|  |
| --- |
|  |
| Steve Chadban RPA Medal#17CDE0 | Professor Steve Chadban BMed(hons), PhD, FRACP, FAHMSStream Director of Renal Medicine and UrologySydney Local Health DistrictRoyal Prince Alfred Hospital, Sydney, AustraliaProfessor of Medicine, Kidney Node-CPC, University of Sydney, Australia |
| Summary:Professor Steve Chadban received the University Medal for Medicine at the University of Newcastle, NSW, completed physician training in Newcastle, Nephrology training and a PhD at Monash, Victoria, Australia. Following his PhD, Chadban completed post-doctoral studies in immunology at the University of Cambridge, UK. He led the Monash Transplantation Program from 1999–2002 then moved to Royal Prince Alfred Hospital, Sydney, Australia, where he is Clinical Stream Director of Renal Medicine and Urology, Senior Staff Nephrologist/transplant physician, Professor of Medicine and Leader of the Kidney Node, Charles Perkins Centre, University of Sydney. Professor Chadban is Past-President of the Transplantation Society of Australia and New Zealand and ex-Councilor of The Transplantation Society, Lead Investigator in the CARSK, BEST Fluids and AusDiab Kidney Studies. Chadban advises Government as Chair of the Transplant Advisory Group to the Organ and Tissue Authority, Co-chair of the COVID19 Rapid Response Taskforce for Donation and Transplantation, and Chair of the National Chronic Kidney Disease Expert Advisory Group (AIHW). He was elected Fellow of the Australian Academy of Health and Medical Sciences in 2017. Chadban co-chaired the 2020 KDIGO Guidelines on the evaluation of candidates for Kidney transplantation, the Global standard in kidney transplant management. Chadban is Associate Editor for the American Journal of Transplantation. He has spoken at numerous national and international meetings and has produced over 400 papers published in journals including the *New England Journal of Medicine, JAMA, Annals, Lancet* and the *Journal of Clinical Investigation*. His publications have been cited 21,829 times and his H-index is 81. Research interests include CKD and ESKD epidemiology, the molecular mechanisms of transplant rejection and CKD, with a focus on the kidney-gut microbiome axis, and improving outcomes for kidney transplant recipients through clinical trials. As a clinician-scientist, Chadban hopes to see lab discoveries translated into human studies and adopted into practice to improve the lives of people living with kidney disease. |
|  |

**Professor STEVEN JAMES CHADBAN** *CURRICULUM VITAE in brief, 2019.*

Steven James Chadban, B.Med(Hons, Uni.Medal), FRACP, FAHMS, PhD.

Born: 8.7.67 at Newcastle, NSW, Australia.

Current Address: Transplantation, Level 9E, Royal Prince Alfred Hospital

Missenden Road, Camperdown, NSW 2050

Phone 612 9515 7120

Fax: 612 9515 6329

Email: steve.chadban@health.nsw.gov.au

**Academic Record**.

Primary **Captain & Dux**,Merewether Public School, Newcastle, 1972-1978.

High School **Captain & Dux**, top 0.5% of NSW, Merewether High, Newcastle, 79-84

**University**: University of Newcastle, NSW, Australia, 1985-1989.

**BMed(Hons), First in year Prize & University Medal for Medicine**.

**Post-Graduate Studies**:

 ECFMG (USA board examination for foreign graduates), Pass 1991.

 Royal Australasian College of Physicians 1993-1996.**FRACP** (Nephrology), 1996.

 **PhD**, Monash University, Victoria 1995-1997. NH&MRC PhD fellowship.

 Post-Doc, Jacquot Travelling Fellow 1998, University of Cambridge, UK.

**Current Positions:**

Clinical Stream Director, Renal and Urology, Sydney Local Area Health District

Director of Renal Medicine, Royal Prince Alfred Hospital and SLHD, Sydney

Clinical Professor (Renal Medicine), University of Sydney.

Leader, Kidney Node, Charles Perkins Centre, University of Sydney

Fellow, Australian Academy of Health and Medical Sciences

Chair, CKD-Expert Advisory Group, Australian Institute of Health and Welfare

Co-Chair, KDIGO Guidelines on Candidate Suitability for Kidney Transplantation

Chair, Transplant Advisory Group, Australian Organ and Tissue Authority

Co-Chair, COVID-19 National Rapid Response Group, Donation & Transplantation

Past-President, Transplantation Society of Australia and New Zealand (2015-17)

Past-ANZDATA Executive officer (2014-2020), Past ANZDATA Chair (2007-2013)

PhD supervisor: 5 current PhD students, 15 completions

Chief investigator: AusDiab Kidney studies, CARSK Trial, BEST Fluids study

Associate Editor, American Journal of Transplantation

Reviewer: NEJM, Lancet, BMJ, JAMA, Kidney Int., AJKD, JASN, MJA

**Prizes:** University Medal – Medicine, Newcastle University 1989

McKenzie Prize for Outstanding contribution to Transplantation, TSANZ 2008

 TJ Neale Prize for Outstanding Contribution to Nephrology in ANZ, ANZSN 2011

 RPA Foundation Research Medal, 2011

Best Scientific Presentation, ANZSN ASM 2007

 The Big Idea, SLHD, Sydney 2019 ($45,000)

**Research funding**: Career funding exceeds $20millionAUD

 PhD Fellowship, NH&MRC, 1995-7 $ 75,000

 Jacquot plus ANZSN Travelling Fellowships 1998 $ 55,000

 NH&MRC project grant 1999-2001 $ 150,000

 (AusDiab I & II, NHMRC, Industry (Co-invest.) 99-07 $ 10,000,000)\*

 AusDiab II Kidney, KHA plus RPAH (CIA) 2004-2006 $ 600,000

 NH&MRC – AusDiab 3(2011-14), #1007544 (CIE) $ 2,537,113

 AusDiab 3 Kidney Study, Amgen Grant 2008-10 $ 750,000

 NH&MRC CCRE (APP219277, CIF) 2003-7 $ 2,000,000

 NHMRC Cap Grant (APP457281, CID) 2007-11 $ 2,616,629

 NHMRC Project Grant(CIA), #402539 2006-8 $ 394,040

 NHMRC Project Grant(CIA), #512489 2008-10 $ 475,500

 CARG Grant – Post-transplant diabetes, 2004 $ 20,000

Burden of CKD, KHA (Co-investigator), 2005 $ 80,000

 NH&MRC Project Grant(CIA) #632673 2010-12 $ 400,000

ARC Grant, Organ donation, DP0985187 (CIE**) 2010-12** $ 240,000

RPA Research Foundation Medal, 2011 $ 50,000

RPA Transplantation Foundation, 2011-12 $ 100,000

NHMRC Project Grant (CIA) #1029601 2012-14 $ 489,255

NHMRC Project Grant #1029205 (CIA) 2012-15 $ 641,010

NHMRC Project Grant #1064500 (CIA), 2014-16 $ 617,562

NHMRC Project #1084454 (CARSK – CIA), 2015-20 $ 1,173,486

NHMRC Project Grant #967,004 (CIA), 2016-2020 $ 967,004

MRFF “BEST Fluids” (#1152390, CIA), 2018-2022 $ 1,152,876

CIHR Project “CARSK” (AI), 2018-2023 $ 2,237,625 (CAN)

 NHMRC Project grant (CIA, microbiota) 2018-2023 $ 1,150,000

**Research Activity**.

**Publications** (348 publications, **citations 23,912, H Index 80** (Google Scholar), including:

1. Collins MG, Fahim MA, Pascoe EM, Hawley CM, Johnson DW, Varghese J, Hickey LE, Clayton PA, Gill JS, Dansie KB, McConnochie RC, Vergara LA, Kiriwandeniya C, Reidlinger D, Mount PF, Weinberg L, McArthur CJ, Coates PT, Endre ZH, Goodman D, Howard K, Howell M, Jamboti JS, Kanellis J, Laurence JM, Lim WH, McTaggart SJ, O'Connell PJ, Pilmore HL, Wong G and **Chadban SJ**. Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial. The Lancet, 2023; 402:105-117. doi:10.1097/TXD.0000000000001399. PMID: 36479278
2. Shi B, Ying T, **Chadban SJ**. Survival after kidney transplantation compared with ongoing dialysis for people over 70 years of age: a matched-pair analysis. Am J Transplant. 2023 Jul 17:S1600-6135(23)00578-6. doi: 10.1016/j.ajt.2023.07.006
3. Stoler S, Chan M, **Chadban SJ**. Nutrition in the management of kidney transplant recipients. J Ren Nutr. 2023 Jul 21:S1051-2276(23)00108-5. doi: 10.1053/j.jrn.2023.07.001. Epub ahead of print. PMID: 37482148.
4. Athavale A, Miles N, Pais R, Snelling P, **Chadban SJ**. Transdermal Magnesium for the Treatment of Peripheral Neuropathy in Chronic Kidney Disease: A Single-Arm, Open-Label Pilot Study. J Palliat Med. 2023 Jul 25. doi: 10.1089/jpm.2023.0229. Epub ahead of print. PMID: 37486715.
5. Shi B, Ying T, Xu J, Wyburn K, Laurence J, **Chadban SJ**. Obesity is Associated With Delayed Graft Function in Kidney Transplant Recipients: A Paired Kidney Analysis. Transpl Int. 2023 May 30;36:11107. doi: 0.3389/ti.2023.11107. PMID: 37324221;
6. Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, **Chadban SJ**, Bowen DG, Chen AC, Damian DL. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N Engl J Med. 2023 Mar 2;388(9):804-812.
7. Josephson MA, Becker Y, Budde K, Kasiske BL, Kiberd B, Loupy A, Małyszko J, Mannon RB, Tönshoff B, Cheung M, Jadoul M, Winkelmayer WC, Zeier M; for Conference Participants. Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 May 24:S0085-2538(23)00382-4. doi: 10.1016/j.kint.2023.05.010
8. Li YJ, Ma J, Loh YW, **Chadban SJ**, Wu H. Short-chain fatty acids directly exert anti-inflammatory responses in podocytes and tubular epithelial cells exposed to high glucose. Front Cell Dev Biol. 2023 May 4;11:1182570. doi:10.3389/fcell.2023.1182570. PMID: 37215085
9. Sommerer C, Legendre C, Citterio F, Watarai Y, Oberbauer R, Basic-Jukic N, Han J, Gawai A, Bernhardt P, **Chadban S**. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study. Transplantation. 2023 Mar 24. doi: 10.1097/TP.0000000000004555.
10. **Chadban SJ**, Singer J, Coates PT. That sinking gut feeling: is transplant-induced dysbiosis contributing to allograft outcomes? Kidney Int. 2023 Mar;103(3):454-457.
11. Jackson S, Combes A, Latif E, Tran M, Lam S, Gore N, Utsiwegota M, Mawson J, Smith L, Palma C, Laurence J, Crawford M, Pulitano C, Wyburn K, **Chadban S**, Leslie S, Vasilaras A. Laparoscopic donor nephrectomy-technique and peri-operative outcomes in an Australian transplant center. Clin Transplant. 2023 Feb 19:e14945. doi: 10.1111/ctr.14945.
12. Irish GL, McMichael LC, Kadatz M, Boudville N, Campbell S, **Chadban S,** Chang D, Kanellis J, Sharples E, Gill JS, Clayton PA. The living kidney donor profile index fails to discriminate allograft survival: implications for its use in kidney paired donation programs. Am J Transplant. 2023 Feb;23(2):232-238. doi: 10.1016/j.ajt.2022.10.001.
13. Nickerson PW, Böhmig GA, **Chadban S**, Kumar D, Mannon RB, van Gelder T, Lee JC, Adler S, Chong E, Djamali A. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design. Trials. 2022 Dec 22;23(1):1042. doi:10.1186/s13063-022-06897-3.
14. Jian Tan, Duan Ni, Jemma Taitz, Gabriela Veronica Pinget, Mark Read, Alistair Senior, Jibran Abdul Wali, Reem Elnour, Erin Shanahan, Huiling Wu, **Steven J. Chadban**, Ralph Nanan, Nicholas Jonathan Cole King, Georges Emile Grau, Stephen J. Simpson, Laurence Macia. Dietary protein increases T-cell-independent sIgA production through changes in gut microbiota-derived extracellular vesicles. Nat Commun. 2022; 13: 4336. Published online 2022 Jul 27. doi: 10.1038/s41467-022-31761-y
15. Collins MG, Fahim MA, Pascoe EM, Hawley CM, Johnson DW, Varghese J, Hickey LE, Clayton PA, Gill JS, Dansie KB, McConnochie RC, Vergara LA, Kiriwandeniya C, Reidlinger D, Mount PF, Weinberg L, McArthur CJ, Coates PT, Endre ZH, Goodman D, Howard K, Howell M, Jamboti JS, Kanellis J, Laurence JM, Lim WH, McTaggart SJ, O'Connell PJ, Pilmore HL, Wong G, **Chadban SJ**. Baseline Characteristics and Representativeness of Participants in the BEST-Fluids Trial: A Randomized Trial of Balanced Crystalloid Solution Versus Saline in Deceased Donor Kidney Transplantation. Transplant Direct. 2022 Nov 4;8(12):e1399. doi: 10.1097/TXD.0000000000001399. PMID: 36479278; PMCID: PMC9722559.
16. Singer J, Tunbridge M, Perkins GB, Salehi T, Ying T, Wu H, Coates PT, **Chadban SJ**. Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin - study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients. BMJ Open. 2022 Dec 1;12(12):e062747. doi: 10.1136/bmjopen-2022-062747. PMID: 36456021; PMCID: PMC9716412.
17. Tangri N, **Chadban S**, Cabrera C, Retat L, Sánchez JJG. Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD. Adv Ther.2022 Oct 28:1–17. doi: 10.1007/s12325-022-02353-5. Epub ahead of print. PMID:36307575; PMCID: PMC9616410.
18. Tunbridge M, Perkins GB, Singer J, Salehi T, Ying T, Grubor-Bauk B, Barry S, Sim B, Hissaria P, **Chadban SJ**, Coates PT. Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients. Trials. 2022 Sep 15;23(1):780. doi: 10.1186/s13063-022-06634-w. PMID: 36109788; PMCID:PMC9477178.
19. Wang YM, Shaw K, Zhang GY, Chung EYM, Hu M, Cao Q, Wang Y, Zheng G, Wu H, **Chadban SJ**, McCarthy HJ, Harris DCH, Mackay F, Grey ST, Alexander SI. Interleukin-33 Exacerbates IgA Glomerulonephritis in Transgenic Mice Overexpressing B Cell Activating Factor. J Am Soc Nephrol. 2022 May;33(5):966-984. doi: 10.1681/ASN.2021081145. Epub 2022 Apr 6. PMID: 35387873; PMCID: PMC9063894.
20. Lai C, **Chadban SJ**, Loh YW, Kwan TK, Wang C, Singer J, Niewold P, Ling Z, Spiteri A, Getts D, King NJC, Wu H. Targeting inflammatory monocytes by immune-modifying nanoparticles prevents acute kidney allograft rejection. Kidney Int.2022 Nov;102(5):1090-1102. doi: 10.1016/j.kint.2022.06.024. Epub 2022 Jul 16. PMID: 35850291.
21. Talbot B, Farnbach S, Tong A, **Chadban S**, Sen S, Garvey V, Gallagher M, Knight J. Patient and Clinician Perspectives on the use of Remote Patient Monitoring in Peritoneal Dialysis. Can J Kidney Health Dis. 2022; 9: 20543581221084499.
22. Julian Singer, Leyla J. Aouad, Kate Wyburn, David M. Gracey, Tracey Ying, **Steven J. Chadban.** The Utility of Pre- and Post-Transplant Oral Glucose Tolerance Tests: Identifying Kidney Transplant Recipients With or at Risk of New Onset Diabetes After Transplant. Transpl Int. 2022; 35: 10078. Published online 2022 Mar 17. PMCID: PMC8967957
23. Perkins GB, Tunbridge M, Salehi T, Sheng Chai C, Kireta S, Johnston J, Penko D, Nitschke J, Yeow AEL, Al-Delfi Z, Drogemuller CJ, Garcia-Valtanen PG, Masavuli MG, Hope CM, Singer J, Aggarwal A, Stella AO, Turville SG, Hurtado PR, Barry SC, Hissaria P, Grubor-Bauk B, **Chadban SJ**\*, Coates PT\*. Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19. Kidney Int. 2022 May; 101(5): 1077–1080. Published online 2022 Mar 16. PMCID: PMC8923876
24. Vinson AJ, Singh S, **Chadban S**, Cherney D, Gaber O, Gill JS, Helgeson E, Herzog CA, Jardine M, Jha V, Kasiske BL, Mannon RB, Michos ED, Mottl AK, Newby K, Roy-Chaudhury P, Sawinski D, Sharif A, Sridhar VS, Tuttle KR, Vock DM, Matas A. Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. J Am Soc Nephrol. 2022 Apr;33(4):665-673. PMID: 35292438; PMCID: PMC8970447
25. Athavale A, Wyburn K, Snelling P, **Chadban SJ**. Dialysis Disequilibrium: Is Acidosis More Important than Urea? Case Rep Nephrol. 2022; 2022: 4964033.
26. Lim WH, Ooi E, Pilmore HL, Johnson DW, McDonald SP, Clayton P, Hawley C, Mulley WR, Francis R, Collins MG, Jaques B, Larkins NG, Davies CE, Wyburn K, Chadban SJ, Wong G. Interactions Between Donor Age and 12-Month Estimated Glomerular Filtration Rate on Allograft and Patient Outcomes After Kidney Transplantation. Transpl Int. 2022 Feb 7;36:10199. doi: 10.3389/ti.2022.10199.
27. Pascoe EM, Chadban SJ, Fahim MA, Hawley CM, Johnson DW, Collins MG; BEST-fluids Investigators; Australasian Elaine M. Pascoe, **Steven J. Chadban**, Magid A. Fahim, Carmel M. Hawley, David W. Johnson, Michael G. Collins, for the BEST-fluids Investigators and the Australasian Kidney Trials Network. Statistical analysis plan for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a randomised controlled trial of the effect of intravenous fluid therapy with balanced crystalloid versus saline on the incidence of delayed graft function in deceased donor kidney transplantation. Trials. 2022; 23: 52.
28. Kidney Trials Network. Correction to: Statistical analysis plan for better evidence for selecting transplant fluids (BEST-fluids): a randomised controlled trial of the effect of intravenous fluid therapy with balanced crystalloid versus saline on the incidence of delayed graft function in deceased donor kidney transplantation. Trials. 2022 Feb7;23(1):123. doi: 10.1186/s13063-022-06050-0. Erratum for: Trials. 2022 Jan18;23(1):52. PMID: 35130942; PMCID: PMC8819917.
29. Sobels E, Best M, Chadban S, Pais R. End Stage Kidney Disease Patient Experiences of Renal Supportive Care in an Australian Teaching Hospital – A Qualitative Study. J Pain Symptom Manage. 2022; 63:737-746.
30. Toussaint ND, Damasiewicz MJ, Holt SG, Lu ZX, Magliano DJ, Atkins RC, Chadban SJ, Shaw JE, Polkinghorne KR. Relationship Between Urinary Phosphate and All- Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study. J Ren Nutr. 2021 Dec 14:S1051-2276(21)00275-2. doi: 10.1053/j.jrn.2021.10.009. Epub ahead of print. PMID: 34920931.
31. Xu J, D'Souza K, Lau NS, Leslie S, Lee T, Yao J, Lam S, Sandroussi C, Chadban S, Ying T, Pleass H, Laurence JM. Staged versus concurrent native nephrectomy and renal transplantation in patients with autosomal dominant polycystic kidney disease: A systematic review. Transplant Rev (Orlando). 2022 Jan;36(1):100652. doi: 10.1016/j.trre.2021.100652. Epub 2021 Sep 16. PMID: 34688508.
32. Boyle S, Tobin JWD, Perram J, Hamad N, Gullapalli V, Barraclough A, Singaraveloo L, Han MH, Blennerhassett R, Nelson N, Johnston AM, Talaulikar D, Karpe K, Bhattacharyya A, Cheah CY, Subramoniapillai E, Bokhari W, Lee C, Hawkes EA, Jabbour A, Strasser SI, Chadban SJ, Brown C, Mollee P, Hapgood G. Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. Hemasphere. 2021 Oct 11;5(11):e648. doi: 10.1097/HS9.0000000000000648. PMID: 34651103; PMCID: PMC8505336.
33. Lai C, Yee SY, Ying T, Chadban S. Biomarkers as diagnostic tests for delayed graft function in kidney transplantation. Transpl Int. 2021 Dec;34(12):2431-2441. doi: 10.1111/tri.14132. Epub 2021 Nov 14. PMID: 34626503.
34. Drak, D., Tangirala, N., Fink, M., Adams, L., Fawcett, J., Jeffrey, G., Byrne, M., McCaughan, G., Chadban, S., Wyburn, K., Gracey, D., et al (2021). Trends and Outcomes in Simultaneous Liver and Kidney Transplantation in Australia and New Zealand. *Transplantation Proceedings*, 53(1), 136-140.
35. Singer, J., Li, Y., Ying, T., Aouad, L., Gracey, D., Wyburn, K., Macia, L., Wu, H., Chadban, S. Protocol for a pilot single-centre, parallel-arm, randomised controlled trial of dietary inulin to improve gut health in solid organ transplantation: The DIGEST study. *BMJ Open*, 11(4); 2021
36. Aubert O, Divard G, Pascual J, Oppenheimer F, Sommerer C, Citterio F, Tedesco H, **Chadban S**, Henry M, Vincenti F, Srinivas T, Watarai Y, Legendre C, Bernhardt P, Loupy A. Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open. 2021 Oct 7;11(10):e052138.
37. Middleton TL, **Chadban S**, Molyneaux L, D'Souza M, Constantino MI, Yue DK, McGill M, Wu T, Twigg SM, Wong J. Young adult onset type 2 diabetes versus type 1 diabetes: Progression to and survival on renal replacement therapy. J Diabetes Complications. 2021 Nov;35(11):108023.
38. Au EH, Wong G, Howard K, Chapman JR, Castells A, Roger SD, Bourke MJ, Macaskill P, Turner R, Lim WH, Lok CE, Diekmann F, Cross N, Sen S, Allen RD, **Chadban SJ**, Pollock CA, Tong A, Teixeira-Pinto A, Yang JY, Kieu A, James L, Craig JC. Factors Associated With Advanced Colorectal Neoplasia in Patients With CKD. Am J Kidney Dis. 2021 Aug 27:S0272-6386
39. Haidar F, Issa N, Gourinat AC, Savalle M, Chalus E, Laurence J, **Chadban S**, Wyburn K. The "New Caledonia COVID-19 Paradox": Dramatic Indirect Impact of the Pandemic on Organ Donation and Transplantation in a Nonprevalence Country. Kidney Int Rep. 2021 Sep;6(9):2519-2520.
40. **Chadban SJ**, Knoll GA. The Authors' Reply: Type 2 Diabetes and Simultaneous Pancreas-kidney Transplantation. Transplantation. 2021 Aug 1;105(8):e93
41. Wyld MLR, Wyburn KR, Chadban SJ. Global Perspective on Kidney Transplantation: Australia. Kidney360. 2021 Aug 5;2(10):1641-1644.
42. Karimi Galougahi K, **Chadban S**, Mehran R, Bangalore S, Chertow GM, Ali ZA. Invasive Management of Coronary Artery Disease in Advanced Renal Disease. Kidney Int Rep. 2021 Mar 24;6(6):1513-1524.
43. Huuskes BM, Scholes-Robertson N, Guha C, Baumgart A, Wong G, Kanellis J, **Chadban S**, Barraclough KA, Viecelli AK, Hawley CM, Kerr PG, Coates PT, Amir N, Tong A. Kidney transplant recipient perspectives on telehealth during the COVID-19 pandemic. Transpl Int. 2021 Jun 11.
44. Anderson MA, Ying T, Wyburn K, Ferguson PM, Strach MC, Grimison P, **Chadban S**, Gracey DM. Transplant-associated penile Kaposi sarcoma managed with single agent paclitaxel chemotherapy: a case report. BMC Urol. 2021 Jun 7;21(1):87.
45. Liu Y, Li YJ, Loh YW, Singer J, Zhu W, Macia L, Mackay CR, Wang W, **Chadban SJ**, Wu H. Fiber Derived Microbial Metabolites Prevent Acute Kidney Injury Through G-Protein Coupled Receptors and HDAC Inhibition. Front Cell Dev Biol. 2021 Apr 8;9:648639.
46. Lee T, D'Souza K, Hameed A, Yao J, Lam S, **Chadban S**, Ying T, Celermajer D, Sandroussi C, Pleass HCC, Laurence JM. Comparison of the effect of single vs dual antiplatelet agents on post-operative haemorrhage after renal transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2021 Jan;35(1):100594.
47. Tong A, Sorrell TC, Black AJ, Caillaud C, Chrzanowski W, Li E, Martinez-Martin D, McEwan A, Wang R, Motion A, Bedoya AC, Huang J, Azizi L, Eggleton BJ; COVID-19 Sensor Research Priority-Setting Investigators. Research priorities for COVID-19 sensor technology. Nat Biotechnol. 2021 Feb;39(2):144-147.
48. Krishnan A, Teixeira-Pinto A, Lim WH, Howard K, Chapman JR, Castells A, Roger SD, Bourke MJ, Macaskill P, Williams G, Lok CE, Diekmann F, Cross N, Sen S, Allen RDM, **Chadban SJ**, Pollock CA, Turner R, Tong A, Yang JYH, Williams N, Au E, Kieu A, James L, Francis A, Wong G, Craig JC. Health-Related Quality of Life in People Across the Spectrum of CKD. Kidney Int Rep. 2020 Oct 3;5(12):2264-2274.
49. Hanlon LV, Agostinho N, D'Souza K, Lee T, **Chadban S**, Pleass HCC, Verran DJ, Laurence JM. Renal Transplant Artery Autologous Saphenous Vein Graft Aneurysms: Late Presentation and the Need for Recall and surveillance. Exp Clin Transplant. 2020 Nov;18(6):725-728.
50. Gilbert A, Robertson L, Heron JE, **Chadban S**, Ndhlovu C, Dahwa RF, Gracey DM. Risk factors for development of acute kidney injury in hospitalised adults in Zimbabwe. PLoS One. 2020 Oct 26;15(10):e0241229.
51. Wong G, Marsh J, Howell M, Lim WH, **Chadban S**, Coates T, Hawley C, Campbell S, Larkins N, Snelling T, Allan L, Teixeira-Pinto A, Reidlinger D, Wyburn K, Craig JC. Screening and Management Practices for Polyoma (BK) Viremia and Nephropathy in Kidney Transplant Recipients From the Lands Down Under: Addressing the Unknowns and Rationale for a Multicenter Clinical Trial. Kidney Int Rep. 2020 Jul 10;5(10):1777-1780.
52. **Chadban SJ**, McDonald M, Wyburn K, Opdam H, Barry L, Coates PT. Significant impact of COVID-19 on organ donation and transplantation in a low-prevalence country: Australia. Kidney Int. 2020 Dec;98(6):1616-1618.
53. Vaughan E, Connolly E, Hui M, **Chadban S**. Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity? Cancer Rep (Hoboken). 2020 ct;3(5):e1250.
54. Mugino M, Lee T, Lam S, Hameed A, Sandroussi C, **Chadban S**, Pleass H, Lawrence JM. Prophylactic Wound Drainage in Renal Transplant: A Survey of Practice Patterns in Australia and New Zealand. Exp Clin Transplant. 2020 Dec;18(7):771-777.
55. Drak D, Tangirala N, Fink M, Adams LA, Fawcett J, Jeffrey GP, Byrne M, McCaughan G, **Chadban S,** Wyburn K, Wong G, Lim WH, Gracey DM. Trends and Outcomes in Simultaneous Liver and Kidney Transplantation in Australia and New Zealand. Transplant Proc. 2021 Jan-Feb;53(1):136-140.
56. Ying T, Shi B, Kelly PJ, Pilmore H, Clayton PA, Chadban SJ. Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. J Am Soc Nephrol. 2020 Dec;31(12):2887-2899.
57. Ying T, Gill JS, **Chadban S**. Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med. 2020 Sep 10;383(11):1091.
58. Hanlon LV, Agostinho N, D'Souza K, Lee T, **Chadban S,** Pleass HCC, Verran DJ, Laurence JM. Renal Transplant Artery Autologous Saphenous Vein Graft Aneurysms: Late Presentation and the Need for Recall and Surveillance. Exp Clin Transplant. 2020 Nov;18(6):725-728.
59. Gilbert A, Robertson L, Heron JE, **Chadban S**, Ndhlovu C, Dahwa RF, Gracey DM. Risk factors for development of acute kidney injury in hospitalised adults in Zimbabwe. PLoS One. 2020 Oct 26;15(10):e0241229.
60. Wong G, Marsh J, Howell M, Lim WH, **Chadban S**, Coates T, Hawley C, Campbell S, Larkins N, Snelling T, Allan L, Teixeira-Pinto A, Reidlinger D, Wyburn K, Craig JC. Screening and Management Practices for Polyoma (BK) Viremia and Nephropathy in Kidney Transplant Recipients From the Lands Down Under: Addressing the Unknowns and Rationale for a Multicenter Clinical Trial. Kidney Int Rep. 2020 Jul 10;5(10):1777-1780.
61. Vaughan E, Connolly E, Hui M, **Chadban S**. Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity? Cancer Rep (Hoboken). 2020 Oct;3(5):e1250.
62. Mugino M, Lee T, Lam S, Hameed A, Sandroussi C, **Chadban S,** Pleass H, Laurence JM. Prophylactic Wound Drainage in Renal Transplant: A Survey of Practice Patterns in Australia and New Zealand. Exp Clin Transplant. 2020 Sep 17.
63. Drak D, Tangirala N, Fink M, Adams LA, Fawcett J, Jeffrey GP, Byrne M, McCaughan G, **Chadban S**, Wyburn K, Wong G, Lim WH, Gracey DM. Trends and Outcomes in Simultaneous Liver and Kidney Transplantation in Australia and New Zealand. Transplant Proc. 2020 Sep 12:S0041-1345(20)32695-6.
64. Ying T, Shi B, Kelly PJ, Pilmore H, Clayton PA, **Chadban SJ**. Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. J Am Soc Nephrol. 2020 Sep 9:ASN.2020050566.
65. Sivam S, Yee BJ, **Chadban SJ**, Piper AJ, Hanly PJ, Wang D, Wong KKH, Grunstein RR. Prevalence of chronic kidney disease in obesity hypoventilation syndrome and obstructive sleep apnoea with severe obesity. Sleep Med. 2020 Oct;74:73-77.
66. Lai C, Anderson M, Davis R, Anderson L, Wyburn K, **Chadban S**, Gracey D. Strongyloides hyperinfection in an HIV-positive kidney transplant recipient: a case report. BMC Infect Dis. 2020 Aug 18;20(1):613.
67. Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, Matsushita K, Surapaneni A, Brunskill N, **Chadban SJ**, Chang AR, Cirillo M, Daratha KB, Gansevoort RT, Garg AX, Iacoviello L, Kayama T, Konta T, Kovesdy CP, Lash J, Lee BJ, Major RW, Metzger M, Miura K, Naimark DMJ, Nelson RG, Sawhney S, Stempniewicz N, Tang M, Townsend RR, Traynor JP, Valdivielso JM, Wetzels J, Polkinghorne KR, Heerspink HJL; Chronic Kidney Disease Prognosis Consortium. Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis. Ann Intern Med. 2020 Sep 15;173(6):426-435.
68. Guha C, Tong A, Baumgart A, Scholes-Robertson N, Isbel N, Kanellis J, Campbell S, Coates T, **Chadban S.** Suspension and resumption of kidney transplant programs during the COVID-19 pandemic: perspectives from patients, caregivers and potential living donors-a qualitative study. Transpl Int. 2020 Jul 8:10.1111/tri.13697. doi: 10.1111/tri.13697.
69. Stock PG, Wall A, Gardner J, Domínguez-Gil B, **Chadban S**, Muller E, Dittmer I, Tullius SG; TTS Ethics Committee. Ethical Issues in the COVID Era: Doing the Right Thing Depends on Location, Resources, and Disease Burden. Transplantation. 2020 Jul;104(7):1316-1320.
70. Wu H, Singer J, Kwan TK, Loh YW, Wang C, Tan J, Li YJ, Lai SWC, Macia L, Alexander SI, **Chadban SJ**. Gut Microbial Metabolites Induce Donor-Specific Tolerance of Kidney Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids. J Am Soc Nephrol. 2020 Jul;31(7):1445-1461.
71. Collins MG, Fahim MA, Pascoe EM, Dansie KB, Hawley CM, Clayton PA, Howard K, Johnson DW, McArthur CJ, McConnochie RC, Mount PF, Reidlinger D, Robison L, Varghese J, Vergara LA, Weinberg L, **Chadban SJ**; BEST-Fluids Investigators and the Australasian Kidney Trials Network. Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation. Trials. 2020 May 25;21(1):428.
72. Li YJ, Chen X**, K**wan TK, Loh YW, Singer J, Liu Y, Ma J, Tan J, Macia L, Mackay CR, **Chadban SJ**, Wu H. Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A. J Am Soc Nephrol. 2020 Jun;31(6):1267-1281.
73. **Chadban SJ**, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Knoll GA. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020 Apr;104(4S1 Suppl 1):S11-S103.
74. Lai C, Ying T, Ho PJ, Wyburn K, Gallagher M, **Chadban S**. Successful kidney transplantation in a patient with stable multiple myeloma. Intern Med J. 2020 Apr;50(4):492-494.
75. **Chadban SJ,** Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Balk EM, Gordon CE, Earley A, Rofeberg V, Knoll GA. Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020 Apr;104(4):708-714.
76. Lai C, Newman A, Mawson J, Abou-Daher F, Watson N, Majumdar A, Wyburn K, **Chadban S**, Gracey D. Rapid reduction of high-level pre-formed donor-specific antibodies after simultaneous liver-kidney transplantation: a report of two cases. BMC Nephrol. 2020 Feb 12;21(1):47.
77. Wyld MLR, Morton RL, Aouad L, Magliano D, Polkinghorne KR, **Chadban S**. The impact of comorbid chronic kidney disease and diabetes on health-related quality-of-life: a 12-year community cohort study. Nephrol Dial Transplant. 2020 Mar 14:gfaa031.
78. De La Mata NL, Clayton PA, Kelly PJ, McDonald S, **Chadban S**, Polkinghorne KR, Webster AC. Survival in Living Kidney Donors: An Australian and New Zealand Cohort Study Using Data Linkage. Transplant Direct. 2020 Feb 10;6(3):e533.
79. Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, Lefaucheur C, Montgomery RA, Nickerson P, Tullius SG, Ahn C, Askar M, Crespo M, **Chadban SJ**, Feng S, Jordan SC, Man K, Mengel M, Morris RE, O'Doherty I, Ozdemir BH, Seron D, Tambur AR, Tanabe K, Taupin JL, O'Connell PJ. Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation. 2020 May;104(5):911-922.
80. Delezire A, Celton JL, Touzain F, Biche V, Haidar F, Cantin JF, Tivollier JM, Mesguen C, Carceles O, Lamy T, Saidi K, Allen R, **Chadban S**, Gracey D, Laurence J, Verran D, Mawson J, Wyburn K, Quirin N. Deceased Donor Kidney Transplantation in New Caledonia: A Unique Collaboration With Australia. Transplantation. 2020 Jan;104(1):1-3.
81. Wan SS, **Chadban SJ**, Watson N, Wyburn K. Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients. Am J Transplant. 2020 May;20(5):1351-1364.
82. Ying T, Tran A, Webster AC, Klarenbach SW, Gill J, **Chadban S**, Morton R. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis. Am J Kidney Dis. 2020

May;75(5):693-704.

1. Clayton PA, Dansie K, Sypek MP, White S, **Chadban S**, Kanellis J, Hughes P, Gulyani A, McDonald S. External validation of the US and UK kidney donor risk indices for deceased donor kidney transplant survival in the Australian and New Zealand population. Nephrol Dial Transplant. 2019 Dec 1;34(12):2127-2131.
2. Berger SP, Sommerer C, Witzke O, Tedesco H, **Chadban S**, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J; TRANSFORM investigators. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019 Nov;19(11):3018-3034.
3. Irish GL, **Chadban S**, McDonald S, Clayton PA. Quantifying lead time bias when estimating patient survival in preemptive living kidney donor transplantation. Am J Transplant. 2019 Dec;19(12):3367-3376.
4. Wong G, Hope RL, Howard K, Chapman JR, Castells A, Roger SD, Bourke MJ, Macaskill P, Turner R, Williams G, Lim WH, Lok CE, Diekmann F, Cross NB, Sen S, Allen RDM, **Chadban SJ**, Pollock CA, Tong A, Teixeira-Pinto A, Yang JYH, Williams N, Au EHK, Kieu A, James L, Craig JC. One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study). J Am Soc Nephrol. 2019 Jun;30(6):1061-1072.
5. Flabouris K, **Chadban S**, Ladhani M, Cervelli M, Clayton P. Body mass index, weight-adjusted immunosuppression and the risk of acute rejection and infection after kidney transplantation: a cohort study. Nephrol Dial Transplant. 2019 Dec 1;34(12):2132-2143.
6. Ying T, Gill J, Webster A, Kim SJ, Morton R, Klarenbach SW, Kelly P, Ramsay T, Knoll GA, Pilmore H, Hughes G, Herzog CA, **Chadban S**, Gill JS. Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study. Am Heart J. 2019 Aug;214:175-183.
7. **Chadban S**, Tedesco-Silva H. ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation. Kidney Int. 2019 Jul;96(1):27-30.
8. Wong G, Hope RL, Howard K, Chapman JR, Castells A, Roger SD, Bourke MJ, Macaskill P, Turner R, Williams G, Lim WH, Lok CE, Diekman F, Cross N, Sen S, Allen RDM, **Chadban SJ**, Pollock CA, Tong A, Teixeira-Pinto A, Yang JYH, Williams N, Au E, Kieu A, James L, Craig JC. Authors' Reply. J Am Soc Nephrol. 2019 Nov;30(11):2276-2277.
9. Nelson RG, Grams ME, Ballew SH, Sang Y, Azizi F, **Chadban SJ**, Chaker L, Dunning SC, Fox C, Hirakawa Y, Iseki K, Ix J, Jafar TH, Köttgen A, Naimark DMJ, Ohkubo T, Prescott GJ, Rebholz CM, Sabanayagam C, Sairenchi T, Schöttker B, Shibagaki Y, Tonelli M, Zhang L, Gansevoort RT, Matsushita K, Woodward M, Coresh J, Shalev V; CKD Prognosis Consortium. Development of Risk Prediction Equations for Incident Chronic Kidney Disease. JAMA. 2019; 322(21):2104–14.
10. Ying T, Tran A, Webster AC, Klarenbach SW, Gill J, **Chadban S**, Morton R. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis. Am J Kidney Dis. 2019 Dec 3.
11. Delezire A, Celton JL, Touzain F, Biche V, Haidar F, Cantin JF, Tivollier JM, Mesguen C, Carceles O, Lamy T, Saidi K, Allen R, **Chadban S**, Gracey D, Laurence J, Verran D, Mawson J, Wyburn K, Quirin N. Deceased Donor Kidney Transplantation in New Caledonia: A Unique Collaboration With Australia. Transplantation. 2020 Jan;104(1):1-3.
12. Wan SS, **Chadban SJ**, Watson N, Wyburn K. Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients. Am J Transplant. 2019 Dec 22.
13. Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, **Chadban S**, Grinyó J, Mamode N, Rigotti P, Couzi L, Büchler M, Sandrini S, Dain B, Garfield M, Ogawa M, Richard T, Marks WH; C10-002 Study Group. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant. 2019 Oct;19(10):2865-2875.
14. Wyld MLR, Morton RL, Clayton P, Wong MG, Jardine M, Polkinghorne K, **Chadban S**. The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. Qual Life Res. 2019 Aug;28(8):2081-2090.
15. Ralph AF, Butow P, Craig JC, Wong G, **Chadban SJ**, Luxton G, Gutman T, Hanson CS, Ju A, Tong A. Living kidney donor and recipient perspectives on their relationship: longitudinal semi-structured interviews. BMJ Open. 2019 Apr 4;9(4):e026629.
16. White SL, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, **Chadban S**, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplant Direct. 2018 Dec 20;5(1):e416.
17. Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M; CKD Prognosis Consortium (CKD-PC). Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019 Jan 10;364:k5301.
18. Sacre JW, Magliano DJ, Zimmet PZ, Polkinghorne KR, **Chadban SJ**, Anstey KJ, Shaw JE. Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study. J Alzheimers Dis. 2019;70(s1):S19-S30.
19. Koye DN, Magliano DJ, Reid CM, Pavkov ME, **Chadban SJ**, McDonald SP, Polkinghorne KR, White S, Paul C, Shaw JE. Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013. Am J Kidney Dis. 2019 Mar;73(3):300-308.
20. Ma J, Li YJ, Chen X, Kwan T, **Chadban SJ**, Wu H. Interleukin 17A promotes diabetic kidney injury. Sci Rep. 2019 Feb 19;9(1):2264.
21. Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, Cruzado JM, Sommerer C, Adel Bakr M, Garcia VD, Uyen HD, Russ G, Soo Kim M, Kuypers D, Buchler M, Citterio F, Hernandez Gutierrez MP, Bernhardt P, **Chadban S**; TRANSFORM Investigators. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation. 2019 Sep;103(9):1953-1963.
22. Head GA, Shaw JE, Dunstan DW, Owen N, Magliano DJ, **Chadban S**, Zimmet P. Hypertension, white-coat hypertension and masked hypertension in Australia: findings from the Australian Diabetes, Obesity, and Lifestyle Study 3. J Hypertens. 2019 Aug;37(8):1615-1623.
23. Irish GL, **Chadban S**, McDonald S, Clayton PA. Quantifying lead time bias when estimating patient survival in preemptive living kidney donor transplantation. Am J Transplant. 2019 May 27. doi: 10.1111/ajt.15472.
24. Pascual J, Berger SP, **Chadban SJ**, Citterio F, Kamar N, Hesselink DA, Legendre C, Eisenberger U, Oppenheimer F, Russ GR, Sommerer C, Rigotti P, Srinivas TR, Watarai Y, Henry ML, Vincenti F, Tedesco-Silva H. Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. Transplant Rev (Orlando). 2019 Oct;33(4):191-199.
25. Clayton PA, McDonald SP, Russ GR, **Chadban SJ**. Long-Term Outcomes after Acute Rejection in Kidney Transplant Recipients: An ANZDATA Analysis. J Am Soc Nephrol. 2019 Sep;30(9):1697-1707.
26. Ralph AF, **Chadban SJ**, Butow P, Craig JC, Kanellis J, Wong G, Logeman C, Tong A. The experiences and impact of being deemed ineligible for living kidney donation: Semi-structured interview study. Nephrology (Carlton). 2019 Jul 1.
27. **Chadban S**, Tedesco-Silva H. ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation. Kidney Int. 2019 Jul;96(1):27-30.
28. Ying T, Gill J, Webster A, Kim SJ, Morton R, Klarenbach SW, Kelly P, Ramsay T, Knoll GA, Pilmore H, Hughes G, Herzog CA, **Chadban S**, Gill JS. Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study. Am Heart J. 2019 Aug;214:175-183.
29. Ying T, Wong G, Lim WH, Clayton P, Kanellis J, Pilmore H, Campbell S, O'Connell PJ, Russ G, **Chadban S**. Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials. Transplantation. 2019 Aug;103(8):1705-1713.
30. White SL, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, **Chadban S**, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplant Direct. 2018 Dec 20;5(1):e416.
31. Tangirala N, Singer J, Snelling P, Wyburn K, **Chadban S**, Aouad L, Gracey DM. Emphysematous pyelonpehritis in a dual kidney transplant recipient. Nephrology (Carlton). 2018 Nov;23(11):1064-1065.
32. Yeung J, Vaughan E, **Chadban S**, Saunders J, Thiagarajah N, Brown C. High-dose intravenous methotrexate with high-flux, extended-hours haemodialysis in treatment of primary central nervous system, post-transplant lymphoproliferative disorder and end-stage kidney disease: A case report. Nephrology (Carlton). 2018 Nov;23(11):1063-1064.
33. Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, Tugwell P, Pecoits-Filho R, Crowe S, Harris T, Van Biesen W, Winkelmayer WC, Levin A, Thompson A, Perkovic V, Ju A, Gutman T, Bernier-Jean A, Viecelli AK, O'Lone E, Shen J, Josephson MA, Cho Y, Johnson DW, Sautenet B, Tonelli M, Craig JC; SONG Implementation Workshop Investigators. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 2018 Dec;94(6):1053-1068.
34. Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, Gansevoort RT, Gutierrez OM, Hamano T, Heine GH, Ishikawa S, Jee SH, Kronenberg F, Landray MJ, Miura K, Nadkarni GN, Peralta CA, Rothenbacher D, Schaeffner E, Sedaghat S, Shlipak MG, Zhang L, van Zuilen AD, Hallan SI, Kovesdy CP, Woodward M, Levin A; CKD Prognosis Consortium. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis. 2019 Feb;73(2):206-217.
35. Jayasinghe K, Haber A, Wyburn K, Gracey D, **Chadban S**. Recurrent oxalosis in a combined liver-kidney transplant patient with primary hyperoxaluria type 1 resulting in graft failure. Nephrology (Carlton). 2018 Oct;23(10):962.
36. Wong MG, Ninomiya T, Liyanage T, Sukkar L, Hirakawa Y, Wang Y, Wyld MLR, Morton RL, **Chadban S**, Howard K, Jardine MJ. Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis. Nephrology (Carlton). 2019 Jun;24(6):605-614.
37. Lim WH, Wong G, McDonald SP, Chakera A, Luxton G, Isbel NM, Pilmore HL, Barbour T, Hughes P, **Chadban SJ**. Long-term outcomes of kidney transplant recipients with end-stage kidney disease attributed to presumed/advanced glomerulonephritis or unknown cause. Sci Rep. 2018 Jun 13;8(1):9021.
38. Hanson CS, Chapman JR, Gill JS, Kanellis J, Wong G, Craig JC, Teixeira-Pinto A, **Chadban SJ**, Garg AX, Ralph AF, Pinter J, Lewis JR, Tong A. Identifying Outcomes that Are Important to Living Kidney Donors: A Nominal Group Technique Study. Clin J Am Soc Nephrol. 2018 Jun 7;13(6):916-926.
39. Chen X, Ma J, Kwan T, Stribos EGD, Messchendorp AL, Loh YW, Wang X, Paul M, Cunningham EC, Habib M, Alexander IE, Sharland AF**, Chadban SJ,** Wu H. Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice. Sci Rep. 2018 May 29;8(1):8319.
40. Ying T, Wong G, Lim W, Kanellis J, Pilmore H, Campbell S, Masterson R, Walker R, O'Connell P, Russ G, **Chadban S**. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. Am J Transplant. 2018 May 26.
41. Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, **Chadban S**, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991.
42. Knoll GA, **Chadban SJ**. Preexisting Cancer in Transplant Candidates: Time for a Change in Practice? Transplantation. 2018 Jul;102(7):1037-1038.
43. Ying T, Clayton P, Naresh C, **Chadban S**. Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression. BMC Nephrol. 2018 Mar 7;19(1):55.
44. Aouad LJ, Clayton P, Wyburn KR, Gracey DM, **Chadban SJ**. Evolution of glycaemic control and variability after kidney transplant. Transplantation. 2018;102:1563-8
45. Calisa V, Craig JC, Howard K, Howell M, Alexander S, **Chadban S**J, Clayton P, Lim WH, Kanellis J, **Wyburn K**, Johnson DW, McDonald SP, Opdam H, Chapman JR, Yang J, Wong G. Survival and quality of life impact of a risk-based allocation algorithm for deceased donor kidney transplantation. Transplantation. 2018 Feb 26. doi: 10.1097
46. Tong A, Sautenet B, Poggio ED, Lentine KL, Oberbauer R, Mannon R, Murphy B, Padilla B, Chow KM, Marson L, **Chadban S**, Craig JC, Ju A, Manera KE, Hanson CS, Josephson MA, Knoll G; SONG-Tx Graft Health Workshop Investigators. Establishing a Core Outcome Measure for Graft Health: A Standardized Outcomes in Nephrology-Kidney Transplantation (SONG-Tx) Consensus Workshop Report. Transplantation. 2018 Aug;102(8):1358-1366.
47. **Richards KG**, Brennan SO, McCaughan GW, **Chadban SJ**. Novel TOF-MS Means of Quantifying ApoAI Amyloid Protein Load After Combined Liver Kidney Transplantation. Transplantation. 2018 May;102(5):e192-e193.
48. Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, **Chadban SJ**. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis. Transplantation. 2018 Apr;102(4):557-568.
49. Neuen BL, **Chadban SJ**, Demaio AR, Johnson DW, Perkovic V. Chronic kidney disease and the global NCDs agenda. BMJ Glob Health. 2017 Jul 6;2(2):e000380.
50. Thomas B, Matsushita K, Abate KH, Al-Aly Z, Ärnlöv J, Asayama K, Atkins R, Badawi A, Ballew SH, Banerjee A, Barregård L, Barrett-Connor E, Basu S, Bello AK, Bensenor I, Bergstrom J, Bikbov B, Blosser C, Brenner H, Carrero JJ, **Chadban S**, Cirillo M, Cortinovis M, Courville K, Dandona L, Dandona R, Estep K, Fernandes J, Fischer F, Fox C, Gansevoort RT, Gona PN, Gutierrez OM, Hamidi S, Hanson SW, Himmelfarb J, Jassal SK, Jee SH, Jha V, Jimenez-Corona A, Jonas JB, Kengne AP, Khader Y, Khang YH, Kim YJ, Klein B, Klein R, Kokubo Y, Kolte D, Lee K, Levey AS, Li Y, Lotufo P, El Razek HMA, Mendoza W, Metoki H, Mok Y, Muraki I, Muntner PM, Noda H, Ohkubo T, Ortiz A, Perico N, Polkinghorne K, Al-Radaddi R, Remuzzi G, Roth G, Rothenbacher D, Satoh M, Saum KU, Sawhney M, Schöttker B, Shankar A, Shlipak M, Silva DAS, Toyoshima H, Ukwaja K, Umesawa M, Vollset SE, Warnock DG, Werdecker A, Yamagishi K, Yano Y, Yonemoto N, Zaki MES, Naghavi M, Forouzanfar MH, Murray CJL, Coresh J, Vos T; Global Burden of Disease 2013 GFR Collaborators; CKD Prognosis Consortium; Global Burden of Disease Genitourinary Expert Group. Global Cardiovascular and Renal Outcomes of Reduced GFR. J Am Soc Nephrol. 2017 Jul;28(7):2167-2179.
51. Alexander SI, Clayton PA, **Chadban SJ**. Organ Transplantation in Australia. Transplantation. 2017 May;101(5):891-892.
52. Alexander SI, Clayton PA, Chadban SJ. The Authors' Reply. Transplantation. 2017 Nov;101(11):e346.
53. Allen PJ, **Chadban SJ**, Craig JC, Lim WH, Allen RDM, Clayton PA, Teixeira-Pinto A, Wong G. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney Int. 2017 Aug;92(2):461-469.
54. Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, Teixeira-Pinto A, Wong G. The Authors Reply. Kidney Int. 2017 Nov;92(5):1291.
55. O'Connell PJ, Kuypers D, Mannon RR, Abecassis M, **Chadban S**, Gill JS, Murphy B, Nickerson PW, Schold JD, Stock P, Seron D, Alloway R, Bromberg J, Budde K, JordanS, Legendre C, Lefaucheur C, Sarwall M, Segev D, Stegall MD, Tullius SG, Wong G, Woodle ES, Ascher N, Morris RE. Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction. Transplantation 2017; 101(7):1527-1534
56. Manera KE, Hanson CS, Chapman JR, Kanellis J, Gill J, Craig JC, Chadban SJ, Wong G, Ralph AF, Tong A. Expectations and Experiences of Follow-up and Self-Care After Living Kidney Donation: A Focus Group Study. Transplantation. 2017 Oct;101(10):2627-2635
57. Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, **Chadban SJ**. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney Int. 2017 Apr;91(4):954-963.
58. Sautenet B, Tong A, Manera KE, Chapman JR, Warrens AN, Rosenbloom D, Wong G, Gill J, Budde K, Rostaing L, Marson L, Josephson MA, Reese PP, Pruett TL, Hanson CS, O'Donoghue D, Tam-Tham H, Halimi JM, Shen JI, Kanellis J, Scandling JD, Howard K, Howell M, Cross N, Evangelidis N, Masson P, Oberbauer R, Fung S, Jesudason S, Knight S, Mandayam S, McDonald SP, Chadban S, Rajan T, Craig JC. Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals. Transplantation. 2017 Aug;101(8):1875-1886.
59. de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group.Early Conversion From Calcineurin Inhibitor- to Everolimus-Based TherapyFollowing Kidney Transplantation: Results of the Randomized ELEVATE Trial. Am J Transplant. 2017 Jul;17(7):1853-1867.
60. Lim WH, Wong G, Pilmore HL, McDonald SP, **Chadban SJ**. Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. Lancet Diabetes Endocrinol. 2017 Jan;5(1):26-33.
61. Ralph AF, Butow P, Hanson CS, **Chadban SJ**, Chapman JR, Craig JC, Kanellis J, Luxton G, Tong A. Donor and Recipient Views on Their Relationship in LivingKidney Donation: Thematic Synthesis of Qualitative Studies. Am J Kidney Dis. 2017;69(5):602-616.
62. Wong G, Chakera A, Chapman JR, **Chadban SC**, Pilmore H, Craig JC, Lim WH. Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system? Transpl Infect Dis. 2017 Feb;19(1).
63. Clayton PA, Lim WH, Wong G, **Chadban SJ**. Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants. J Am Soc Nephrol. 2016 Nov;27(11):3440-3446.
64. **Chadban SJ**. Josette Marie Eris April 7, 1959 to April 6, 2016 TTS Councilor and Professor. Transplantation. 2016 Aug;100(8):1596.
65. Lopez-Vargas PA, Tong A, Howell M, Phoon RK, Chadban SJ, Shen Y, Craig JC. Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease - a mixed-methods study. Nephrology (Carlton). 2017 May;22(5):374-381
66. Wyld ML, Chadban SJ, Morton RL. Improving Our Understanding of Quality of Life in CKD. Am J Kidney Dis. 2016 Jun;67(6):820-1.
67. Clayton PA, Saunders JR, McDonald SP, Allen RD, Pilmore H, Saunder A, Boudville N, Chadban SJ. Risk-Factor Profile of Living Kidney Donors: The Australia and New Zealand Dialysis and Transplant Living Kidney Donor Registry 2004-2012. Transplantation. 2016 Jun;100(6):1278-83.
68. Kwan TK, Chadban SJ, Wu H. Toll-Like Receptor 4 Deficiency Improves Short-term Renal Function but not Long-term Graft Survival in a Fully MHC-Mismatched Murine Model of Renal Allograft Transplantation. Transplantation. 2016 Jun;100(6):1219-27.
69. Braza F, Brouard S, Chadban S, Goldstein DR. Role of TLRs and DAMPs in allograft inflammation and transplant outcomes. Nat Rev Nephrol. 2016 May;12(5):281-90.
70. Pilmore H, Chadban S. Cardiac Screening for Kidney Transplantation: The Clinical Conundrum Continues. Transplantation. 2016 Mar;100:1396-7
71. Barr E, Reutens A, Magliano D, Wolfe R, Lu Z, Sikaris K, Tanamas S, Atkins R, Chadban S, Shaw J, Polkinghorne K. Cystatin C estimated glomerular filtration rate and all-cause and cardiovascular disease mortality risk in the general population: AusDiab study. Nephrology (Carlton). 2016 Mar 3. doi: 10.1111/nep.12759. [Epub ahead of print] PubMed PMID: 26938304.
72. Wyld ML, Chadban SJ. Recurrent IgA Nephropathy After Kidney Transplantation. Transplantation. 2016 Feb 18. [Epub ahead of print] PubMed PMID: 26895219.
73. Ralph AF, Alyami A, Allen RD, Howard K, Craig JC, Chadban SJ, Irving M, Tong A. Attitudes and beliefs about deceased organ donation in the Arabic-speaking community in Australia: a focus group study. BMJ Open. 2016 Jan 19;6(1):e010138. doi: 10.1136/bmjopen-2015-010138. PubMed PMID: 26787253; PubMed Central PMCID: PMC4735320.
74. Lim WH, Chadban SJ. Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms. J Am Soc Nephrol. 2016 May;27(5):1272-5. doi: 10.1681/ASN.2015091021. Epub 2015 Nov 12. PubMed PMID: 26563385.
75. Wong G, Chua S, Chadban SJ, Clayton P, Pilmore H, Hughes PD, Ferrari P, Lim WH. Waiting Time Between Failure of First Graft and Second Kidney Transplant and Graft and Patient Survival. Transplantation. 2015 Oct 9. [Epub ahead of print] PubMed PMID: 26457605.
76. Howard K, Jan S, Rose JM, Wong G, Craig JC, Irving M, Tong A, **Chadban S**, Allen, RD, Cass A. Preferences for Policy Options for Deceased Organ Donation for Transplantation: A Discrete Choice Experiment. Transplantation. 2015 Oct 9. [Epub ahead of print] PubMed PMID: 26457603.
77. Hanson CS, Chadban SJ, Chapman JR, Craig JC, Wong G, Tong A. Nephrologists' Perspectives on Recipient Eligibility and Access to Living Kidney Donor Transplantation. Transplantation. 2015 Oct 1.
78. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25.
79. Zykova SN, Storhaug HM, Toft I, Chadban SJ, Jenssen TG, White SL. Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Tromsø study. Nutr J. 2015 May 14;14:49.
80. Wyld ML, Lee CM, Zhuo X, White S, Shaw JE, Morton RL, Colagiuri S, Chadban SJ. Cost to government and society of chronic kidney disease stage 1-5: a national cohort study. Intern Med J. 2015 Jul;45(7):741-7.
81. Tong A, Crowe S, Chando S, Cass A, Chadban SJ, Chapman JR, Gallagher M, Hawley CM, Hill S, Howard K, Johnson DW, Kerr PG, McKenzie A, Parker D, Perkovic V, Polkinghorne KR, Pollock C, Strippoli GF, Tugwell P, Walker RG, Webster AC, Wong G, Craig JC. Research Priorities in CKD: Report of a National Workshop Conducted in Australia. Am J Kidney Dis. 2015 Aug;66(2):212-22.
82. Clayton PA, Aouad L, Wyburn KR, Eris JM, Chadban SJ. HbA1c Is Insensitive at Month 3 After Kidney Transplantation. Transplantation. 2015 May;99(5):e37-8.
83. Wang AY, Bellomo R, Cass A, Finfer S, Gattas D, Myburgh J, Chadban S, Hirakawa Y, Ninomiya T, Li Q, Lo S, Barzi F, Sukkar L, Jardine M, Gallagher MP; POST-RENAL Study Investigators and the ANZICS Clinical Trials Group. Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomes. Nephrology (Carlton). 2015 Jul;20(7):492-8.
84. Kwan T, Chadban SJ, Ma J, Bao S, Alexander SI, Wu H. IL-17 deficiency attenuates allograft injury and prolongs survival in a murine model of fully MHC-mismatched renal allograft transplantation. Am J Transplant. 2015 Jun;15(6):1555-67.
85. Aggarwal S, Sukkar L, Wynter L, Richards K, Cheung J, Chadban SJ. Dangers of broth after transplantation. Nephrology (Carlton). 2015 Apr;20(4):297-9.
86. Howard K, Jan S, Rose JM, Wong G, Irving M, Tong A, Craig JC, Chadban S, Allen RD, Cass A. Community preferences for the allocation of donor organs for transplantation: a discrete choice study. Transplantation. 2015 Mar;99(3):560-7.
87. Lim WH, Gray NA, Chadban SJ, Pilmore H, Wong G. Graft and patient outcomes of zero-human leucocyte-antigen-mismatched deceased and live donor kidney transplant recipients. Transpl Int. 2015 May;28(5):610-8.
88. Wyld ML, Clayton PA, Kennedy SE, Alexander SI, Chadban SJ. Pregnancy outcomes for kidney transplant recipients with transplantation as a child. JAMA Pediatr. 2015 Feb;169(2):e143626.
89. Hanson CS, Chadban SJ, Chapman JR, Craig JC, Wong G, Ralph AF, Tong A. The expectations and attitudes of patients with chronic kidney disease toward living kidney donor transplantation: a thematic synthesis of qualitative studies. Transplantation. 2015 Mar;99(3):540-54.
90. Mudaliar H, Pollock C, Ma J, Wu H, Chadban S, Panchapakesan U. The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose. PLoS One. 2014 Oct 10;9(10):e108844.
91. Chadban SJ, Staplin ND. Is it time to increase access to transplantation for those with diabetic end-stage kidney disease? Kidney Int. 2014 Sep;86(3):464-6.
92. Kwan T, Wu H, Chadban SJ. Macrophages in renal transplantation: Roles and therapeutic implications. Cell Immunol. 2014 Sep-Oct;291(1-2):58-64.
93. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS; CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014 Jun 25;311(24):2518-31.
94. Clayton PA, McDonald SP, Snyder JJ, Salkowski N, Chadban SJ. External Validation of the Estimated Posttransplant Survival Score for Allocation of Deceased Donor Kidneys in the United States. Am J Transplant. 2014 Jun 5.
95. White S, Chadban S. Diabetic Kidney Disease in Australia: Current Burden and Future Projections. Nephrology (Carlton). 2014;19:450-8.
96. Ma J, Chadban SJ, Zhao CY, Chen X, Kwan T, Panchapakesan U, Pollock CA, Wu H. TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. PLoS One. 2014 May 19;9(5):e97985.
97. Irving MJ, Jan S, Tong A, Wong G, Craig JC, Chadban S, Rose J, Cass A, Allen RD, Howard K. What factors influence people's decisions to register for organ donation? The results of a nominal group study. Transpl Int. 2014, Jun;27(6):617-24.
98. Ma J, Wu H, Zhao CY, Panchapakesan U, Pollock C, Chadban SJ. Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. Int J Clin Exp Pathol. 2014 Jan 15;7(2):481-95.
99. Sud R, Garry L, Spicer ST, Allen RD, Eris JM, Wyburn K, Verran D, Cooper CL, Chadban S. A role for everolimus in post-transplant encapsulating peritoneal sclerosis: first case report. Nephrology (Carlton). 2014 Apr;19 Suppl 1:27-30.
100. Getts DR, Terry RL, Getts MT, Deffrasnes C, Müller M, van Vreden C, Ashhurst TM, Chami B, McCarthy D, Wu H, Ma J, Martin A, Shae LD, Witting P, Kansas GS, Kühn J, Hafezi W, Campbell IL, Reilly D, Say J, Brown L, White MY, Cordwell SJ, Chadban SJ, Thorp EB, Bao S, Miller SD, King NJ. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med. 2014 Jan 15;6(219):219ra7.
101. Lopez-Vargas PA, Tong A, Phoon RK, Chadban SJ, Shen Y, Craig JC. Knowledge deficit of patients with stage 1-4 CKD: a focus group study. Nephrology (Carlton). 2014 Apr;19(4):234-43.
102. Wu H, Steenstra R, de Boer EC, Zhao CY, Ma J, van der Stelt JM, Chadban SJ. Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice. Kidney Int. 2014 Apr;85(4):824-32.
103. Storhaug HM, Norvik JV, Toft I, Eriksen BO, Løchen ML, Zykova S, Solbu M, White S, Chadban S, Jenssen T. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study. BMC Cardiovasc Disord. 2013 Dec 11;13:115.
104. Wu H, Chadban SJ. Roles of Toll-like receptors in transplantation. Curr Opin Organ Transplant. 2014 Feb;19(1):1-7.
105. Chadban SJ, Eris JM, Kanellis J, Pilmore H, Lee PC, Lim SK, Woodcock C, Kurstjens N, Russ G; the SOCRATES Study Group. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int. 2013 Nov 27. doi: 10.1111/tri.12252.
106. Wyld ML, Clayton PA, Jesudason S, Chadban SJ, Alexander SI. Pregnancy outcomes for kidney transplant recipients. Am J Transplant. 2013 Dec;13(12):3173-82.
107. Wyld ML, Clayton PA, Morton RL, Chadban SJ. Anti-coagulation, anti-platelets or no therapy in haemodialysis patients with atrial fibrillation: A decision analysis. Nephrology (Carlton). 2013 Dec;18(12):783-9.
108. Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, Rothenbacher D, Sarnak MJ, Astor BC, Coresh J, Levey AS, Gansevoort RT; CKD Prognosis Consortium. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013 Sep 5;369(10):932-43.
109. Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis. 2013 Dec;62(6):1095-101.
110. Irving MJ, Tong A, Jan S, Wong G, Cass A, Allen RD, Craig JC, Chadban S, Rose J, Howard K. Community preferences for the allocation of deceased donor organs for transplantation: a focus group study. Nephrol Dial Transplant. 2013 Aug;28(8):2187-93.
111. Damasiewicz MJ, Magliano DJ, Daly RM, Gagnon C, Lu ZX, Sikaris KA, Ebeling PR, Chadban SJ, Atkins RC, Kerr PG, Shaw JE, Polkinghorne KR. Serum 25-hydroxyvitamin D deficiency and the 5-year incidence of CKD. Am J Kidney Dis. 2013 Jul;62(1):58-66.
112. Wyburn KR, **Chadban SJ**, Kwan T, Alexander SI, Wu H: Interleukin-18 binding protein therapy is protective in adriamycin nephropathy, American journal of physiology Renal physiology 2013, 304:F68-76
113. Mudaliar H, Pollock CA, Komala MG, Chadban SJ, Wu H, Panchapakesan U. THE ROLE OF TOLL-LIKE RECEPTOR PROTEINS (TLR) 2 AND 4 IN MEDIATING INFLAMMATION IN PROXIMAL TUBULES. Am J Physiol Renal Physiol. 2013 Jul 15:305;F143-154
114. Didsbury M, McGee RG, Tong A, Craig JC, Chapman JR, **Chadban S**, Wong G. Exercise training in solid organ transplant recipients: a systematic review and meta-analysis. Transplantation. 2013 Mar 15;95(5):679-87.
115. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn BR; Chronic Kidney Disease Prognosis Consortium. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ. 2013 Jan 29;346:f324
116. Lim WH, Clayton P, Wong G, Campbell SB, Cohney S, Russ GR, **Chadban SJ**, McDonald SP: Outcomes of Kidney Transplantation From Older Living Donors, Transplantation 2013, 95:106-113
117. Kwan TK, **Chadban SJ**, McKenzie PR, Saunders JR: Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria, Nephrology (Carlton) 2013, 18:241-242
118. **Chadban S**, Eris J, Russ G, Campbell S, Chapman J, Pussell B, Trevillian P, Ierino F, Thomson N, Hutchison B, Irish A, Woodcock C, Kurstjens N, Walker R: Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients, Nephrology (Carlton) 2013, 18:63-70
119. Wu H, Noordmans GA, O'Brien MR, Ma J, Zhao CY, Zhang GY, Kwan TK, Alexander SI, Chadban SJ: Absence of MyD88 signaling induces donor-specific kidney allograft tolerance, J Am Soc Nephrol 2012, 23:1701-1716
120. Wong G, Howard K, Chapman JR, Chadban S, Cross N, Tong A, Webster AC, Craig JC: Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities, PLoS One 2012, 7:e29591
121. Wong G, Howard K, Chapman J, Pollock C, Chadban S, Salkeld G, Tong A, Williams N, Webster A, Craig JC: How do people with chronic kidney disease value cancer-related quality of life?, Nephrology (Carlton) 2012, 17:32-41
122. Vacher-Coponat H, McDonald S, Clayton P, Loundou A, Allen RD, Chadban SJ: Inferior Early Posttransplant Outcomes for Recipients of Right Versus Left Deceased Donor Kidneys: An ANZDATA Registry Analysis, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012,
123. Tong A, Jan S, Wong G, Craig JC, Irving M, Chadban S, Cass A, Marren N, Howard K: Patient preferences for the allocation of deceased donor kidneys for transplantation: a mixed methods study, BMC nephrology 2012, 13:18
124. Tong A, Jan S, Wong G, Craig JC, Irving M, Chadban S, Cass A, Howard K: Rationing scarce organs for transplantation: healthcare provider perspectives on wait-listing and organ allocation, Clinical transplantation 2012,
125. Sparke C, Moon L, Green F, Mathew T, Cass A, Chadban S, Chapman J, Hoy W, McDonald S: Estimating the Total Incidence of Kidney Failure in Australia Including Individuals Who Are Not Treated by Dialysis or Transplantation, Am J Kidney Dis 2013;61:413-9
126. Roberts DM, Jiang SH, Chadban SJ: The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review, Transplantation 2012, 94:775-783
127. Polkinghorne KR, Chadban SJ: A decade after the KDOQI CKD guidelines: a perspective from Australia, Am J Kidney Dis 2012, 60:725-726
128. Naresh CN, Hayen A, Craig JC, Chadban SJ: Day-to-Day Variability in Spot Urine Protein-Creatinine Ratio Measurements, Am J Kidney Dis 2012,
129. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warnock DG, Wen CP, Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS: Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate, JAMA 2012, 307:1941-1951
130. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang L, Coresh J, de Jong PE, Astor BC: Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis, Lancet 2012, 380:1649-1661
131. Lim WH, Dogra G, Chadban SJ, Campbell SB, Clayton P, Cohney S, Russ GR, McDonald SP: Lack of impact of donor age on patient survival for renal transplant recipients >/=60years, Transplant international 2012, 25:401-408
132. Lim WH, Clayton P, Wong G, Dogra G, Budgeon CA, Murray K, Campbell SB, Cohney S, Russ GR, Polkinghorne KR, Chadban SJ, McDonald SP: Association between initial and pretransplant dialysis modality and graft and patient outcomes in live- and deceased-donor renal transplant recipients, Transplant international : official journal of the European Society for Organ Transplantation 2012, 25:1032-1040
133. Lim WH, Chadban SJ, Clayton P, Budgeon CA, Murray K, Campbell SB, Cohney S, Russ GR, McDonald SP: Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients, Clinical transplantation 2012, 26:E428-437
134. Ko HT, Yin JL, Wyburn K, Wu H, Eris JM, Hambly BD, Chadban SJ: Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction, Nephrol Dial Transplant 2012 Feb;28(2):327-36,
135. Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Chadban SJ, Usherwood T, Polkinghorne K, Colagiuri S, Jerums G, Macisaac R, Martin H: Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement, Med J Aust 2012, 197:224-225
136. Irving MJ, Tong A, Jan S, Cass A, Rose J, Chadban S, Allen RD, Craig JC, Wong G, Howard K: Factors that influence the decision to be an organ donor: a systematic review of the qualitative literature, Nephrol Dial Transplant 2012, 27:2526-2533
137. Irving MJ, Tong A, Jan S, Cass A, Chadban S, Allen RD, Craig JC, Wong G, Howard K: Community attitudes to deceased organ donation: a focus group study, Transplantation 2012, 93:1064-1069
138. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J: Age and association of kidney measures with mortality and end-stage renal disease, JAMA 2012, 308:2349-2360
139. Gill JS, Schaeffner E, Chadban S, Dong J, Rose C, Johnston O, Gill J: Quantification of the Early Risk of Death in Elderly Kidney Transplant Recipients, Am J. Trans. 2012,
140. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG: Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis, Lancet 2012, 380:1662-1673
141. Damasiewicz MJ, Magliano DJ, Daly RM, Gagnon C, Lu ZX, Ebeling PR, Chadban SJ, Atkins RC, Kerr PG, Shaw JE, Polkinghorne KR: 25-hydroxyvitamin D levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and Lifestyle) study, BMC nephrology 2012, 13:55
142. Clayton PA, McDonald SP, Chapman JR, Chadban SJ: Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial, Transplantation 2012, 94:152-158
143. Chadban SJ, Barraclough KA, Campbell SB, Clark CJ, Coates PT, Cohney SJ, Cross NB, Eris JM, Henderson L, Howell MR, Isbel NM, Kanellis J, Kotwal SS, Manley P, Masterson R, Mulley W, Murali K, O'Connell P, Pilmore H, Rogers N, Russ GR, Walker RG, Webster AC, Wiggins KJ, Wong G, Wyburn KR: KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients, Nephrology (Carlton) 2012, 17:204-214
144. Chadban S, Eris, Russ G, Campbell S, Chapman J, Pussell B, Trevillian P, Ierino F, Thomson N, Hutchison B, Irish A, Woodcock C, Kurstjens N, Walker R: Enteric-Coated Mycophenolate Sodium (EC-MPS) in Combination with Full Dose or Reduced Dose Cyclosporine, Basiliximab and Corticosteroids in Australian De Novo Kidney Transplant Patients, Nephrology (Carlton) 2012,
145. Wong G, Howard K, Chapman JR, Tong A, Bourke M, Hayen A, Macaskill P, Hope RL, Williams N, Kieu A, Allen R, Chadban S, Pollock C, Webster AC, Roger S, Craig JC: Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol, BMC Public Health 2011, 11:516
146. White SL, Yu R, Craig JC, Polkinghorne KR, Atkins RC, Chadban SJ: Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community, Am J Kidney Dis 2011, 58:19-28
147. White SL, Polkinghorne KR, Chadban SJ: Population prevalence of proteinuria and diagnostic accuracy of urine dipsticks, Am J Kidney Dis 2011, 58:1039; author reply 1039-1040
148. White SL, Dunstan DW, Polkinghorne KR, Atkins RC, Cass A, Chadban SJ: Physical inactivity and chronic kidney disease in Australian adults: the AusDiab study, Nutr Metab Cardiovasc Dis 2011, 21:104-112
149. Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD, Zimmet PZ, Chadban SJ, Polkinghorne KR, Shaw JE, O'Dea K: High rates of albuminuria but not of low eGFR in Urban Indigenous Australians: the DRUID Study, BMC Public Health 2011, 11:346
150. Lim WH, Chadban S, Campbell S, Cohney S, Russ G, McDonald S: A review of utility-based allocation strategies to maximize graft years of deceased donor kidneys, Nephrology (Carlton) 2011, 16:368-376
151. Lim WH, Chadban S, Campbell S, Cohney S, Russ G, McDonald S: A Review Of Utility-Based Allocation Strategies To Maximise Graft Years Of Deceased Donor Kidneys, Nephrology (Carlton) 2011,
152. Irving MJ, Tong A, Jan S, Cass A, Rose J, Chadban S, Allen RD, Craig JC, Wong G, Howard K: Factors that influence the decision to be an organ donor: a systematic review of the qualitative literature, Nephrol Dial Transplant 2011,
153. Howard K, Jan S, Rose J, Chadban S, Allen RD, Irving M, Tong A, Wong G, Craig JC, Cass A: Community Preferences for the Allocation &Donation of Organs - The PAraDOx Study, BMC Public Health 2011, 11:386
154. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, Jong PE, Coresh J, de Jong PE, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Wang Y, Atkins RC, Polkinghorne KR, Chadban SJ, Shankar A, Klein R, Klein BE, Sacks F, Curhan G, Shlipak M, Sarnak MJ, Katz R, Fried LP, Hallan S, Lydersen S, Holmen J, Lee BJ, Ishani A, Neaton J, Svendsen K, Iseki K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Auguste P, Veldhuis K, Camarata L, Thomas B, Manley T: Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts, Kidney Int 2011,
155. Chen GE, Wu H, Ma J, Chadban SJ, Sharland A: Toll-like receptor 4 engagement contributes to expression of NKG2D ligands by renal tubular epithelial cells, Nephrol Dial Transplant 2011, 26:3873-3881
156. Chan M, Patwardhan A, Ryan C, Trevillian P, Chadban S, Westgarth F, Fry K: Evidence-based guidelines for the nutritional management of adult kidney transplant recipients, J Ren Nutr 2011, 21:47-51
157. Clayton P, McDonald SP, Chadban SJ. Steroids and recurrent IgA nephropathy after kidney transplantation. AmJTransplant, 2011;11:1645-9. [IF 7.1]
158. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, Chadban SJ: HMGB1 contributes to kidney ischemia reperfusion injury, J Am Soc Nephrol 2010, 21:1878-1890
159. Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD,

Zimmet PZ, Chadban SJ, Polkinghorne KR, Shaw JE, O'Dea K. High rates of

albuminuria but not of low eGFR in urban indigenous Australians: the DRUID study.

BMC Public Health. 2011 May 19;11:346. PubMed PMID: 21595912; PubMed Central

PMCID: PMC3112138.

PubMed Central PMCID: PMC3125368.

1. Wong G, Howard K, Chapman JR, Tong A, Bourke MJ, Hayen A, Macaskill P, Hope

RL, Williams N, Kieu A, Allen R, Chadban S, Pollock C, Webster A, Roger SD, Craig

JC. Test performance of faecal occult blood testing for the detection of bowel

cancer in people with chronic kidney disease (DETECT) protocol. BMC Public

Health. 2011 Jun 29;11:516. PubMed PMID: 21714917;

1. Wong G, Howard K, Chapman J, Pollock C, Chadban S, Salkeld G, Tong A, Williams

N, Webster A, Craig JC. How do people with chronic kidney disease value cancer

related quality of life? Nephrology (Carlton). 2011 Oct 23. doi:

1. White S, Yu R, Craig J, Polkinghorne K, Atkins RC, Chadban SJ. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general population. Am.J.Kid.Dis. 2011;58:19-28 [IF4.0]
2. Chan M, Patwardhan A, Ryan C, Trevillian P, Chadban S, Westgarth F, Fry K. [Evidence-based guidelines for the nutritional management of adult kidney transplant recipients.](http://www.ncbi.nlm.nih.gov/pubmed/21195919) J Ren Nutr. 2011 Jan;21(1):47-51.
3. Lim WH, Chadban S, Campbell S, Cohney S, Russ G, McDonald S. [A Review Of Utility-Based Allocation Strategies To Maximise Graft Years Of Deceased Donor Kidneys.](http://www.ncbi.nlm.nih.gov/pubmed/21265932) Nephrology (Carlton). 2011 Jan 26.
4. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, Jong PE, Coresh J; The Chronic Kidney Disease Prognosis Consortium, Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Wang Y, Atkins RC, Polkinghorne KR, Chadban SJ, Shankar A, Klein R, Klein BE, Sacks F, Curhan G, Shlipak M, Sarnak MJ, Katz R, Fried LP, Hallan S, Lydersen S, Holmen J, Lee BJ, Ishani A, Neaton J, Svendsen K, Iseki K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Auguste P, Veldhuis K, Camarata L, Thomas B, Manley T. [Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts.](http://www.ncbi.nlm.nih.gov/pubmed/21289597) Kidney Int. 2011 Feb 2. [Epub ahead of print] [IF 5.9]
5. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, Chadban SJ. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol. 2010 ;21(11):1878-90 [IF 6.9]
6. Lynch BM, White SL, Owen N, Healy GN, Chadban SJ, Atkins RC, Dunstan DW. Television viewing time and risk of chronic kidney disease in adults: the AusDiab Study. Ann Behav Med. 2010;40(3):265-74.
7. Lim WH, Chang S, Chadban S, Campbell S, Dent H, Russ GR, McDonald SP. Donor-recipient age matching improves years of graft function in deceased-donor kidney transplantation. Nephrol Dial Transplant. 2010 Sep;25(9):3082-9.
8. Chadban SJ, Wu H, Hughes J. Macrophages and kidney transplantation. Semin Nephrol. 2010 May;30(3):278-89. Review.
9. Lim W, Chadban S, Campbell S, Dent H, Russ G, McDonald S. Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transpl Int. 2010 Dec;23(12):1207-15.
10. Chronic Kidney Disease Prognosis Consortium, Matsushita K, etal. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010 Jun 12;375(9731):2073-81.
11. Lim WH, Chadban SJ, Campbell S, Dent H, Russ GR, McDonald SP. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients. Nephrology 2010;15(3):368-76.
12. Mathew TH, Corso O, Ludlow M, Boyle A, Cass A, Chadban SJ, Joyner B, Shephard M, Usherwood T. Screening for chronic kidney disease in Australia: a pilot study in the community and workplace. Kidney Int Suppl. 2010 Mar;(116):S9-16.
13. Smith GC, Trauer T, Kerr PG, Chadban SJ. Prospective quality-of-life monitoring of simultaneous pancreas and kidney transplant recipients using the 36-item short form health survey. Am J Kidney Dis. 2010 Apr;55(4):698-707.
14. White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab Study. Am J Kidney Dis. 2010 Apr;55(4):660-70.
15. Tong A, Howard K, Jan S, Cass A, Rose J, Chadban S, Allen RD, Craig JC. Community preferences for the allocation of solid organs for transplantation: a systematic review. Transplantation. 2010 Apr 15;89(7):796-805.
16. Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010;89(7):851-7.
17. Tapp RJ, O'Neil A, Shaw JE, Zimmet PZ, Oldenburg BF; AusDiab Study Group. Is there a link between components of health-related functioning and incident impaired glucose metabolism and type 2 diabetes? The Australian Diabetes Obesity and Lifestyle (AusDiab) study. Diabetes Care. 2010 Apr;33(4):757-62.
18. White SL, Dunstan DW, Polkinghorne KR, Atkins RC, Cass A, Chadban SJ. Physical inactivity and chronic kidney disease in Australian adults: The AusDiab study. Nutr Metab Cardiovasc Dis. 2009 Nov 24.
19. Lim WH, Chang SH, Chadban SJ, Campbell SB, Dent H, Russ GR, McDonald SP. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients. Transplantation. 2009;88(10):1208-13.
20. Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, Cass A. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health. 2010;13(2):196-208.
21. Villar E, Polkinghorne KR, Chang SH, Chadban SJ, McDonald SP. Effect of type 2 diabetes on mortality risk associated with end-stage kidney disease. Diabetologia. 2009 Sep 9. [Epub ahead of print] PubMed PMID: 19756481.
22. White S, Polkinghorne K, Cass A, Shaw J, Atkins RC and **Chadban SJ**. Alcohol consumption and 5-year onset of chronic kidney disease: The AusDiab Study. In press Nephrol Dial Transpl 2009;24:2464-72.
23. Tong A, Sainsbury P, **Chadban S,** Walker RG, Harris DC, Carter SM, Hall B, Hawley CM, , Craig JC. Patients' experiences and perspectives of living with kidney disease. Am J Kid Disease. 2009;53:687-700.
24. Howard, K., Salkeld,G., White,S., McDonald,S., **Chadban,S**., Craig,J., Cass,A.  The Cost-Effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology 2009;14:123-32.
25. White SL, Perkovic V, Cass A, Chang CL, Poulter NR, Spector T, Haysom L, Craig JC, Al Salmi I, **Chadban SJ**, Huxley R. Is low birth weight an antecedent of chronic kidney disease in later life? A systematic review of observational studies. *American Journal of Kidney Diseases*, 2009;54:248-61.
26. Fry K, Patwardhan A, Ryan C, Trevillian P, **Chadban S**, Westgarth F, Chan M. Development of evidence-based guidelines for the nutritional management of adult kidney transplant recipients. J Ren Nutr. 2009: 19(1); 101-4
27. White SL, McGeechan K, Jones M, Cass A, **Chadban SJ**, Polkinghorne KR, Perkovic V, Roderick PJ. Socioeconomic disadvantage and kidney disease in the United States, Australia, and Thailand. Am J Public Health. 2008 Jul;98(7):1306-13.
28. H Wu, M Craft, P Wang, G Chen , K Wyburn, B Hambly and **SJ Chadban** . Interleukin-18 contributes to renal damage after ischaemia-reperfusion. J Am Soc Nephrol, 2008; 19: 2331-41. [IF 7.37]
29. Ko H, Hambly BD, Eris JM, Levidiotis V, Wyburn K, Wu H, **Chadban S**J, Yin JL. Dendritic cell derived IL-18 production is inhibited by rapamycin and sangliferin A, but not by cyclosporine A. Transpl Immunol. 2008;20: 99-105.
30. **S Chadban**, R Morris, H Hirsch, S Bunnapradist, W Arns, K Budde. Immunosuppression in renal transplantation: some aspects for the modern era. Transplantation Reviews 2008; 22:241-51[IF 2.1]
31. Walker R, Thomas M, Goodman D, Campbell S, **Chadban S**; on behalf of the AUS-13 study group. Combination therapy with tacrolimus and mycophenolate mofetil: effects of early and late minimization of mycophenolate mofetil after renal transplant. Clin Transplant. 2008; 22:594-602.
32. Tong A, Sainsbury P, Carter SM, Hall B, Harris DC, Walker RG, Hawley CM, **Chadban S**, Craig JC. Patients' priorities for health research: focus group study of patients with chronic kidney disease. Nephrol Dial Transplant. 2008;23:3206-14.
33. White SL, **Chadban SJ**, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ. 2008 Mar;86(3):229-37.
34. **Chadban S**. New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients. Nephrol Dial Transplant. 2008 Jun;23(6):1816-8.
35. White,S, Cass,A., Polkinghorne K, Shaw J, Atkins RC, **Chadban,S**.  Awareness of personal risk of chronic kidney disease among the Australian General Community. Med J Aust. 2007; 188:204-8.
36. [Chang SH, Russ GR, **Chadban S**J, Campbell SB, McDonald SP.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17876274&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005. Nephrology. 2008;13;171-6.
37. [Magliano DJ, Polkinghorne KR, Barr EL, Su Q, Chadban SJ, Zimmet PZ, Shaw JE, Atkins RC.](http://www.ncbi.nlm.nih.gov/pubmed/18003774?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) HPLC-detected albuminuria predicts mortality. *J Am Soc Nephrol*. 2007;18(12):3171-6.
38. [Kondalsamy-Chennakesavan S, Hoy WE, Wang Z, Briganti E, Polkinghorne K, Chadban S, Shaw J; On Behalf of the Ausdiab Study Group.](http://www.ncbi.nlm.nih.gov/pubmed/18203125?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Anthropometric measurements of Australian Aboriginal adults living in remote areas: Comparison with nationally representative findings. *Am J Hum Biol*. 2008;20:317-24.
39. Perkovic V, Cass A, Patel AA, Suriyawongpaisal P, Barzi F, **Chadban S**, MacMahon S, Neal B. High prevalence of chronic kidney disease in Thailand. Kidney Int. 2008;73:473-9.
40. [Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, **Chadban S**J.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17853945&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007 Oct;117(10):2847-59.
41. [Chang SH, Russ GR, **Chadban S**J, Campbell SB, McDonald SP.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17876274&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum)Trends in kidney transplantation in Australia and New Zealand, 1993-2004. Transplantation. 2007 Sep 15;84(5):611-8.
42. [Hoy WE, Kondalsamy-Chennakesavan S, Wang Z, Briganti E, Shaw J, Polkinghorne K, **Chadban S**; AusDiab Study Group.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17461011&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum)Quantifying the excess risk for proteinuria, hypertension and diabetes in Australian Aborigines: comparison of profiles in three remote communities in the Northern Territory with those in the AusDiab study. Aust N Z J Public Health. 2007 Apr;31(2):177-83.
43. Killen JP, **Chadban S**. Antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2007 Feb 8;356(6):634.
44. McClintock C, Cass A, **Chadban SJ**. How to treat: Chronic Kidney Disease. Australian Doctor, Feb 2 2007;19-23.
45. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol J, Uchida K, Pescovitz M, Marchetti P, Tuncer M, Citterio F, Wiecek A, **Chadban S**, El-Shahawy M, Budde K5, Goto N. Results of an international, randomized trial comparing glucose metabolism disorders and efficacy with cyclosporine versus tacrolimus. Am J Transplant, 2007;7:1506-14
46. McDonald S, Russ GR, Campbell S, **Chadban SJ**. Kidney Transplant Rejection in Australia and New Zealand: Relationships between rejection and graft outcome. *Am J Transplant, 2007;7:1-8*
47. **Chadban SJ**, Baines L, Polkinghorne K, etal. Anemia after kidney transplantation is not completely explained by decreased kidney function. Am J Kidney Dis. 2007;49(2):301-9.
48. Cass,A., **Chadban,S**., Craig, J., Howard, H., McDonald, S., Salkeld,G., & White,S.  The Economic Impact of End-Stage Kidney Disease in Australia.  Kidney Health Australia, Melbourne, 2006 [available at [www.kidney.org.au](http://www.kidney.org.au)].
49. Howard, K., Salkeld,G., White,S., **Chadban,S**., Craig,J., McDonald,S., Perkovic,V., & Cass,A.  The Cost-Effectiveness of Early Detection and Intervention to Prevent the Progression of Chronic Kidney Disease in Australia.  Kidney Health Australia, Melbourne, 2006 [available at [www.kidney.org.au](http://www.kidney.org.au)].
50. Wyburn K, Wu H, Chen G, Yin J, Eris J, **Chadban S**. Interleukin-18 affects local cytokine expression but does not impact on the development of kidney allograft rejection. Am J Transplant. 2006;6(11):2612-21.
51. Nguyen D, Ping F, Mu W, Hill P, Atkins RC, **Chadban SJ**. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology 2006;11(3):226-31.
52. Buchler M, **Chadban S**, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases. Nephrol Dial Transplant. 2006;21(1):197-202.
53. Polkinghorne KR, Su Q, **Chadban SJ**, Shaw JE, Zimmet PZ, Atkins RC. Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study: immunonephelometry compared with high-performance liquid chromatography. Am J Kidney Dis. 2006 Apr;47(4):604-13.
54. Wyburn K, Jose M, Wu H, Atkins RC, **Chadban SJ**. The role of macrophages in allograft rejection. **Transplantation** 2005;80:1641-7.
55. Wyburn K, Wu H**,** Yin J, Jose M, Eris J, **Chadban S**. Macrophage deried interleukin 18 in experimental renal allograft rejection. **Nephrol Dial Transplant**2005; 20:699-706.
56. Verran D, Robertson A, Chapman J, **Chadban S**. Non-heart beating donors. Nephrology 2005;10sup4:S116-9.
57. **Chadban SJ**, Ierino FL. Welcome to the era of CKD and the eGFR. **Med J Aust**. 2005;183(3):117-8.
58. Blazik M, Hutchinson P, Jose MD, Polkinghorne KR, Holdsworth SR, Atkins RC, **Chadban SJ**. Leukocyte phenotype and function predicts infection risk in renal transplant recipients. **Nephrol Dial Transplant**. 2005;20(10):2226-30.
59. **Chadban SJ**, Atkins RC. Glomerulonephritis. **Lancet**. 2005;365(9473):1797-806.
60. Yu R, **Chadban S**, Svara F, Sen S, Eris J. Two cases of delayed cyclosporin absorption leading to CsA exposure higher than that predicted by C2 monitoring alone. **Nephrol Dial Transplant**. 2005;20(8):1745-7.
61. Kusyk T, Verran D, Stewart G, Ryan B, Fisher J, Tsacalos K, **Chadban S**, Eris J. Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttransplantation. **Transplant Proc**. 2005;37(2):1026-8.
62. Wyburn K, Jose M, Wu H**,** Atkins RC, **Chadban SJ**. Macrophages in kidney allograft rejection. **Transplantation,** 2005;80:1641-7.
63. Atkins RC, Polkinghorne KR, Briganti EM, Shaw JE, Zimmet PZ, **Chadban SJ**. Prevalence of albuminuria in Australia: the AusDiab Kidney Study. Kidney Int Suppl. 2004 Nov;(92):S22-4.
64. Stefoni S, Midtved K, Cole E, Thervet E, Cockfield S, Buchler M, Toselli L, Pallardo LM, Schena FP, Pilmore H, Kessler M, **Chadban S**, Carreno CA; MO2ART Study Group. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. **Transplantation**. 2005;79(5):577-83.
65. White SL, Cass A, Atkins RC and **Chadban SJ**. Chronic Kidney Disease in the General Population. **Adv Chronic Kidney Dis**, 2005;12:5-13
66. Smith GC, Trauer T, Kerr PG, **Chadban SJ**. Prospective psychosocial monitoring of living kidney donors using the sf-36 health survey: results at 12 months. **Transplantation** 2004;78:1384-9
67. Tapp RJ, Shaw J, **Chadban SJ**, Atkins RC, Zimmett P. Albuminuria is Evident in the Early Stages of Diabetes Onset: results from the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). **Am J Kidney Dis** 2004; 44:792-8
68. Flanc RS, Roberts MA, Strippoli G, **Chadban SJ**, Kerr PG, Atkins RC. Treatment of Proliferative lupus nephritis: A meta-analysis of randomized controlled trials. ***Am J Kidney Dis*** 2004;43:197-208.
69. Flanc RS, Roberts MA, Strippoli G, **Chadban SJ**, Kerr PG, Atkins RC. Treatment of lupus nephritis. Cochrane Database Syst Rev 2004(1):CD002922.Review.
70. **Chadban SJ.** Transplantation. ***ANZDATA Registry 2003 Report*** (ISSN 1329-2870); 66-85.
71. **SJ Chadban.** Waiting List. ***ANZDATA Registry 2003 Report*** (ISSN 1329-2870); 62-65.
72. Jose MD, Ikezumi Y, van Rooijen N, Atkins RC, **Chadban SJ**. Macrophages act as effectors of tissue damage in acute renal allograft rejection **Transplantation** 2003; 76: 1015-1022.
73. Zoungas S, Kerr PG, **Chadban SJ**, Muske C, Ristevski S, Dowick A, Atkins RC, McNeil JJ, McGrath BP. Arterial function after successful renal transplantation. **Kidney Int**. 2004;65:1882-89.
74. Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardo LM, **Chadban SJ**, Pilmore H, Connolly J, Buchler M, Schena FP, Carreno CA, Dandavino R, Cole E. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion **Transplantation** 2003; 76: 903-908.
75. Smith GC, Trauer T, Kerr PG, **Chadban SJ.** Prospective psychosocial monitoring of living kidney donors using the SF-36 health survey **Transplantation** 2003; 76: 807-809.
76. Atkins RC, Briganti EM, Zimmet PZ, **Chadban SJ**. Association between albuminuria and proteinuria in the general population: the AusDiab Study **Nephrol Dial Transplant** 2003; 18: 2170-2174.
77. Chow F, Polkinghorne KR, **Chadban SJ**, Atkins RC and Kerr PG. Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology, 2003;4:177-183.
78. Jose MD, David JR, Atkins RC, **Chadban SJ**. Blockade of macrophage migration inhibitory factor does not prevent acute renal allograft rejection **Am J Transplant** 2003; 3: 1099-1106.
79. Briganti EM, Shaw JE, **Chadban SJ**, Zimmet PZ, Welborn TA, McNeil JJ, Atkins RC. Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab) **Med J Aust** 2003; 179: 135-139.
80. Briganti EM, Atkins RC, **Chadban SJ**. Albuminuria and renal insufficiency prevalence guides population screening **Kidney Int** 2003; 64: 760-761.
81. **Chadban SJ**, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults: The AusDiab kidney study **J Am Soc Nephrol** 2003; 14: S131-S138.
82. Chow F, Polkinghorne K, Saunder A, Kerr P, Atkins RC and **SJ Chadban**. Historical controlled trial of OKT-3 versus basiliximab induction in simultaneous pancreas-renal transplantation. Nephrology, 2003;8:212-6.
83. Russ GR, Campbell S, **Chadban SJ**, Eris J, O'Connell P, Pussell B, Walker R. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients Transplant Proc 2003; 35: 115S-117S.
84. Hutchinson P, **Chadban SJ**, Atkins RC, Holdsworth SR. Laboratory assessment of immune function in renal transplant patients **Nephrol Dial Transplant** 2003; 18: 983-989.
85. Jose MD, Le Meur Y, Atkins RC, **Chadban SJ**. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection **Am J Transplant 2003; 3: 294-300.**
86. Robertson RE, Nikolic-Paterson DJ, Tesch GH, Foti R, Atkins RC and **Chadban SJ**. Role of IL-10 in rat mesangioproliferative glomerulonephritis. Nephrology, 2003;8:33-41.
87. Chow FY, Briganti EM, Kerr PG, **Chadban SJ**, Zimmet PZ, Atkins RC. Health-related quality of life in Australian adults with renal insufficiency: a population-based study **Am J Kidney Dis** 2003; 41: 596-604
88. E Brigantte, RC Atkins, **SJ Chadban**. Recurrent glomerulonephritis and risk of renal allograft loss (letter). **New England J Med.**, 2002;347:1531-2.
89. **SJ Chadban**, E Briganti, PG Kerr, P Zimmet, J Shaw, RC Atkins. Prevalence of kidney damage in the general community – The AusDiab Kidney Study. **J Am Soc Nephrol**, 2003;14(7sup2):S131-8.
90. E Brigantte, G Russ, JJ McNeil, RC Atkins, **SJ Chadban**. Long-term risk of renal allograft loss due to recurrent glomerulonephritis. **New England J Med**., 2002;347:103-9.
91. Y Le Meur, M Jose, W Mu, RC Atkins and **SJ Chadban**. M-CSF expression and macrophage accumulation in renal allograft rejection. **Transplantation**, 2002;8:1318-24.
92. **SJ Chadban**. Glomerulonephritis Recurrence in the Renal Graft. **J Am Soc Nephrol**, 2001; 12: 394-402.
93. E Briganti, P Branley, **SJ Chadban**, P Zimmet, J Shaw, RC Atkins. The effect of smoking on renal function in the general community. Am J Kidney Dis 2002;704-712 (plus editorial).
94. **SJ Chadban** (On behalf of the AusDiab Kidney study team). AusDiab Renal Study: Indicators of renal disease. Nephrology 2002;7 sup 1:S26-9.
95. RC Atkins, S Bennett, **SJ Chadban** et al. AusDiab – The Australian Diabetes, Obesity and lifestyle report. IDI, August 2001.
96. F Brown, D Nikolic-Paterson, **SJ Chadban**, et al. Urine MIF concentrations as a diagnostic tool in human renal allograft rejection. **Transplantatio**n, 2001;71:1777-83.
97. M Blazic, P Hutchison, S Holdsworth, RC Atkins and **SJ Chadban**. Leukocyte phenotype & function predicts infection in renal allograft recipients. Trans Proc. 2001;33:3651.
98. T Robertson, D Nikolic-Paterson, G Tesch, R Foti, RC Atkins and **SJ Chadban**. Role of interleukin-10 in rat mesangioproliferative glomerulonephritis. Nephrology 2003;8:33-41.
99. T Robertson, D Nikolic-Paterson, L Hurst, RC Atkins and **SJ Chadban**. IL-10 mediated mesangial cell proliferation is PDGF dependent. Clin Exp Immunol, 2002;130:241-4.
100. Gilbert R, Kelly DJ, McKay T, **Chadban SJ**, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ. Platelet Derived Growth Factor receptor inhibition ameliorates experimental mesangial proliferative glomerulonephritis. **Kidney Int** 2001;59:1324-32.
101. PG Kerr, **SJ Chadban**, RC Atkins. Is there a role for plasma exchange in rapidly progressive glomerulonephritis. Nephrology, 2001;6:141-3.
102. NR Pritchard, Cutler AJ, Uribe S, **SJ Chadban**, Morley BJ, KGC Smith. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcGammaRII. **Current Biol**, 2000;10:227-30.
103. **SJ Chadban**, G Tesch, R Foti, RC Atkins, D Nikolic-Paterson. IL-10 differentially modulates MHC class II expression by macrophages and mesangial cells. Immunology 1998;94:72-8.
104. **SJ Chadban**, DJ Nikolic-Paterson. IL-10 - is it good or bad for the kidney? Nephrology 1998;4:331-8.
105. **SJ Chadban**, G Tesch, HY Lan, RC Atkins, D Nikolic-Paterson. Effect of IL-10 treatment on experimental crescentic glomerulonephritis in rat. **Kidney Int**., 1997. 51:1809-1817.
106. **SJ Chadban**, GH Tesch, R Foti, RC Atkins and David J Nikolic-Paterson. Interleukin-10 is a mesangial cell growth factor in vitro and in vivo. **Lab. Invest**. 1997;76(5): 619-627.
107. G Tesch, N Yang, H Yu, HY Lan, R Foti, **S Chadban**, RC Atkins and D Nikolic-Paterson. IL-1β is predominantly expressed by intrinsic kidney cells in experimental crescentic glomerulonephritis in rat. Nephrol, Dial and Trans. 1997;12:1109-15.
108. Y. Ng, S. Liu, **S. Chadban**, H.Y. Lan, T. Huang. Recombinant human Erythropoietin for anaemia in Nephrotic Syndrome with Thalassemia. Clin Nephrol 1997;47:273-4

## Textbook chapters

1. SJ Chadban. Chronic allograft dysfunction. In Clinical Cases in Kidney Disease, 1st Edition, Editor D Harris, McGraw-Hill, 2008, pp460-472.
2. SJ Chadban. Post-transplant glomerulonephritis. In Comprehensive Clinical Nephrology, 3rd Edition (2010), Johnson & Feehally eds, Mosby, and 2nd Edition 2006.
3. SJ Chadban, RC Atkins. Management of infection associated glomerulonephritis. In Therapy in Nephrology and Hypertension, Brady & Wilcox Eds., WB Saunders Company, 1999, p115-124. Revised and updated for 2nd Edition, Jan 2003
4. SJ Chadban, JR Bradley, KGC Smith. Clinical Immunosuppression in Renal Transplantation. In Thiru & Waldmann eds, Immunology and Pathology of Transplantation. Blackwell Science, UK, 20.11.2000.
5. Kerr PG, Chadban SJ and Atkins RC. Rapidly Progressive Glomerulonephritis, in Diseases of the Kidney, Seventh Edition. Edited by Schrier RW and Gottschalk CW, In Press July 2000.
6. Kerr PG and Chadban SJ. Volume 6: Renal Disease, Medi+CAL CD-ROM series. Medi+WORLD International Pty Ltd, Hawthorn 3122, Australia.

**Presentations:**

American Society of Transplantation (Chair 2008, 2010, oral presentations 10 over past 10 years including late breaking trials)

ANZSN Annual Scientific Meetings (1995-2022, 26 presentations, 10 orals, 3 invited plenaries)

TSANZ Annual Scientific Meetings 2000-22, 15 oral, 43 posters, Young Investigator award, 5 plenaries)

International Congress of Nephrology (2003, 2005, 2011, 2013 invited plenaries, 1995 & 1997)

American Society of Nephrology ASM (multiple posters, chair roles, SOTA).

Hong Kong Societies of Nephrology and Transplantation, Invited speaker 4 times

Malaysian Society of Transplantation, Plenary Speaker on over 5 occasions

Taiwanese Society of Transplantation, Invited Speaker 2012, 2014

CAST invited plenary speaker 2013, 2015, 2019, 2022

Thai Society of Transplantation, Plenary Speaker 2016

# WHO and ISN CME Lecturer, Bangkok and Ho Chi Minh City, 1999

RACP Physician Training Lectures (RACP, DELTAMED, RPA) 2000-2022

Advanced Training in Nephrology and Transplantation Lectures (2000-2016)

GPCE Plenary presentations 2015 and 2023